US20150274653A1 - Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b - Google Patents
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b Download PDFInfo
- Publication number
- US20150274653A1 US20150274653A1 US14/423,981 US201314423981A US2015274653A1 US 20150274653 A1 US20150274653 A1 US 20150274653A1 US 201314423981 A US201314423981 A US 201314423981A US 2015274653 A1 US2015274653 A1 US 2015274653A1
- Authority
- US
- United States
- Prior art keywords
- compound
- mmol
- alkyl
- mixture
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]N([2*])S(=O)(=O)BC(=O)NC1=CC=CC=C1.[4*]C.[4*]C.[4*]C Chemical compound [1*]N([2*])S(=O)(=O)BC(=O)NC1=CC=CC=C1.[4*]C.[4*]C.[4*]C 0.000 description 35
- ITYZMCQTNCZNHV-YDALLXLXSA-N CC1=CC(NC(=O)C2=C(F)C=CC(S(=O)(=O)N[C@H]3CCOC3)=C2F)=CC=C1F.S Chemical compound CC1=CC(NC(=O)C2=C(F)C=CC(S(=O)(=O)N[C@H]3CCOC3)=C2F)=CC=C1F.S ITYZMCQTNCZNHV-YDALLXLXSA-N 0.000 description 4
- GRXFGXTZTCYAIG-MRVPVSSYSA-N *.CC1=CC=C(S(=O)(=O)N[C@H](C)C(F)(F)F)C(F)=C1C(=O)NC1=CC(Cl)=C(F)C(F)=C1 Chemical compound *.CC1=CC=C(S(=O)(=O)N[C@H](C)C(F)(F)F)C(F)=C1C(=O)NC1=CC(Cl)=C(F)C(F)=C1 GRXFGXTZTCYAIG-MRVPVSSYSA-N 0.000 description 3
- CUOXKRFNJJHRMM-UHFFFAOYSA-N CC1(NS(=O)(=O)C2=C(F)C(C(=O)NC3=CC(F)=C(F)C(Cl)=C3)=C(Cl)C=C2)COC1 Chemical compound CC1(NS(=O)(=O)C2=C(F)C(C(=O)NC3=CC(F)=C(F)C(Cl)=C3)=C(Cl)C=C2)COC1 CUOXKRFNJJHRMM-UHFFFAOYSA-N 0.000 description 3
- OEMABDMOTVCQIG-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC(S(=O)(=O)NCC(F)(F)F)=CC=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC(S(=O)(=O)NCC(F)(F)F)=CC=C2)=C1 OEMABDMOTVCQIG-UHFFFAOYSA-N 0.000 description 3
- JWRNFSDBQSWWRZ-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC(S(=O)(=O)NCC(F)F)=CC=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC(S(=O)(=O)NCC(F)F)=CC=C2)=C1 JWRNFSDBQSWWRZ-UHFFFAOYSA-N 0.000 description 3
- BRMSVTATJVFSAT-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3(C)CC3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3(C)CC3)=C2)=C1 BRMSVTATJVFSAT-UHFFFAOYSA-N 0.000 description 3
- HIPRAZYDNWLPBP-UHFFFAOYSA-N CC1=CC(NC(=O)C2=C(F)C(S(=O)(=O)NC3(C)COC3)=CC=C2C)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=C(F)C(S(=O)(=O)NC3(C)COC3)=CC=C2C)=CC=C1F HIPRAZYDNWLPBP-UHFFFAOYSA-N 0.000 description 3
- ONUAHSFYICLYFM-SBUREZEXSA-N *.*.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H](C)[C@H](O)C3=CC=CC=C3)=C2)=C1 Chemical compound *.*.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H](C)[C@H](O)C3=CC=CC=C3)=C2)=C1 ONUAHSFYICLYFM-SBUREZEXSA-N 0.000 description 2
- VRRNDHDMMHDFFF-KAPRSBACSA-N *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H](C)[C@H](O)C3=CC=CC=C3)=C2)=C1.S Chemical compound *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H](C)[C@H](O)C3=CC=CC=C3)=C2)=C1.S VRRNDHDMMHDFFF-KAPRSBACSA-N 0.000 description 2
- GPVKWQIJNNYLQF-QRIJJCFISA-N *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3C4=CC=CC=C4C[C@@H]3O)=C2)=C1.S Chemical compound *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3C4=CC=CC=C4C[C@@H]3O)=C2)=C1.S GPVKWQIJNNYLQF-QRIJJCFISA-N 0.000 description 2
- MQXUGDBKPZSUKD-BROMNNCMSA-N *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCC4=CC=CC=C4[C@@H]3O)=C2)=C1.S Chemical compound *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCC4=CC=CC=C4[C@@H]3O)=C2)=C1.S MQXUGDBKPZSUKD-BROMNNCMSA-N 0.000 description 2
- FLQMXRDSUHJTKE-CQSZACIVSA-N *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCOC3)=C2)=C1 Chemical compound *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCOC3)=C2)=C1 FLQMXRDSUHJTKE-CQSZACIVSA-N 0.000 description 2
- MHTGNHXUGRPMCG-AWEZNQCLSA-N *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H](C)C3CC3)=C2)=C1 Chemical compound *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H](C)C3CC3)=C2)=C1 MHTGNHXUGRPMCG-AWEZNQCLSA-N 0.000 description 2
- VRRNDHDMMHDFFF-ZXPGKYBVSA-N *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H](C)[C@@H](O)C3=CC=CC=C3)=C2)=C1.S Chemical compound *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H](C)[C@@H](O)C3=CC=CC=C3)=C2)=C1.S VRRNDHDMMHDFFF-ZXPGKYBVSA-N 0.000 description 2
- DVIQZCMPVUAZKD-AEFICSSHSA-N *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCC[C@H]3O)=C2)=C1.S Chemical compound *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCC[C@H]3O)=C2)=C1.S DVIQZCMPVUAZKD-AEFICSSHSA-N 0.000 description 2
- WYKPKIPVJZLOQH-KRWDZBQOSA-N *.CC1=CC(NC(=O)C2=CC(S(=O)(=O)C[C@H](C)C3=CC=CC=C3)=CC=C2)=CC=C1F Chemical compound *.CC1=CC(NC(=O)C2=CC(S(=O)(=O)C[C@H](C)C3=CC=CC=C3)=CC=C2)=CC=C1F WYKPKIPVJZLOQH-KRWDZBQOSA-N 0.000 description 2
- AIQLPLUDKCNNJJ-LLVKDONJSA-N *.CC[C@@H](C)CS(=O)(=O)C1=CC(C(=O)NC2=CC(F)=C(F)C=C2)=C(F)C=C1 Chemical compound *.CC[C@@H](C)CS(=O)(=O)C1=CC(C(=O)NC2=CC(F)=C(F)C=C2)=C(F)C=C1 AIQLPLUDKCNNJJ-LLVKDONJSA-N 0.000 description 2
- LZYBLONNQDOLNZ-CYBMUJFWSA-N *.CC[C@@H](C)CS(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C=C2)=CC=C1 Chemical compound *.CC[C@@H](C)CS(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C=C2)=CC=C1 LZYBLONNQDOLNZ-CYBMUJFWSA-N 0.000 description 2
- UQCUZCPNXXSQPJ-CYBMUJFWSA-N *.CC[C@@H](C)NS(=O)(=O)C1=CC(C(=O)NC2=CC(C)=C(F)C=C2)=CC=C1 Chemical compound *.CC[C@@H](C)NS(=O)(=O)C1=CC(C(=O)NC2=CC(C)=C(F)C=C2)=CC=C1 UQCUZCPNXXSQPJ-CYBMUJFWSA-N 0.000 description 2
- BXEPLPXHIZXQSO-OAHLLOKOSA-N *.O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)N[C@@H]2CCOC2)=C1 Chemical compound *.O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)N[C@@H]2CCOC2)=C1 BXEPLPXHIZXQSO-OAHLLOKOSA-N 0.000 description 2
- SBQFPXYVHKXDLA-UHFFFAOYSA-N C#CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C)=C2)=C1 Chemical compound C#CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C)=C2)=C1 SBQFPXYVHKXDLA-UHFFFAOYSA-N 0.000 description 2
- UYKRICBMQIPDOB-UHFFFAOYSA-N C=CC(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC(C)=C(F)C=C2)=CC=C1 Chemical compound C=CC(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC(C)=C(F)C=C2)=CC=C1 UYKRICBMQIPDOB-UHFFFAOYSA-N 0.000 description 2
- OKXSRFMBLGEUMN-UHFFFAOYSA-N C=CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3(C)COC3)=C2)=C1 Chemical compound C=CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3(C)COC3)=C2)=C1 OKXSRFMBLGEUMN-UHFFFAOYSA-N 0.000 description 2
- LYTFPCSRUUYKLK-UHFFFAOYSA-N CC(C)CS(=O)(=O)C1=C(F)C(C(=O)NC2=CC(C(F)(F)F)=CC=C2)=C(F)C=C1 Chemical compound CC(C)CS(=O)(=O)C1=C(F)C(C(=O)NC2=CC(C(F)(F)F)=CC=C2)=C(F)C=C1 LYTFPCSRUUYKLK-UHFFFAOYSA-N 0.000 description 2
- QCSPPZIOVSTAPW-UHFFFAOYSA-N CC(C)CS(=O)(=O)C1=C(F)C(C(=O)NC2=CC(F)=C(F)C=C2)=C(F)C=C1 Chemical compound CC(C)CS(=O)(=O)C1=C(F)C(C(=O)NC2=CC(F)=C(F)C=C2)=C(F)C=C1 QCSPPZIOVSTAPW-UHFFFAOYSA-N 0.000 description 2
- XKHGYIAQNKSYPU-UHFFFAOYSA-N CC(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC(C(C)C)=C(F)C=C2)=CC=C1 Chemical compound CC(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC(C(C)C)=C(F)C=C2)=CC=C1 XKHGYIAQNKSYPU-UHFFFAOYSA-N 0.000 description 2
- PSSFANOUQLKGML-UHFFFAOYSA-N CC(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC(C(F)(F)F)=C(F)C=C2)=CC=C1 Chemical compound CC(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC(C(F)(F)F)=C(F)C=C2)=CC=C1 PSSFANOUQLKGML-UHFFFAOYSA-N 0.000 description 2
- XULVJSKFFMHODP-UHFFFAOYSA-N CC(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC(C(F)F)=C(F)C=C2)=CC=C1 Chemical compound CC(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC(C(F)F)=C(F)C=C2)=CC=C1 XULVJSKFFMHODP-UHFFFAOYSA-N 0.000 description 2
- PBOZYAMXGRPJFE-UHFFFAOYSA-N CC(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC(C3CC3)=C(F)C=C2)=CC=C1 Chemical compound CC(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC(C3CC3)=C(F)C=C2)=CC=C1 PBOZYAMXGRPJFE-UHFFFAOYSA-N 0.000 description 2
- OOHQBGAZRDHRFB-UHFFFAOYSA-N CC(C)NS(c1cc(C(Nc(cc2)cc(C(F)(F)F)c2F)=O)ccc1)(=O)=O Chemical compound CC(C)NS(c1cc(C(Nc(cc2)cc(C(F)(F)F)c2F)=O)ccc1)(=O)=O OOHQBGAZRDHRFB-UHFFFAOYSA-N 0.000 description 2
- NLVBNZRGJGOLPD-UHFFFAOYSA-N CC1(COC1)NS(c(cc1C(Nc(cc2)cc(F)c2F)=O)ccc1Cl)(=O)=O Chemical compound CC1(COC1)NS(c(cc1C(Nc(cc2)cc(F)c2F)=O)ccc1Cl)(=O)=O NLVBNZRGJGOLPD-UHFFFAOYSA-N 0.000 description 2
- HHSVTZPSETWLSQ-UHFFFAOYSA-N CC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC(Br)=C(F)C=C3)=CC=C2)COC1 Chemical compound CC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC(Br)=C(F)C=C3)=CC=C2)COC1 HHSVTZPSETWLSQ-UHFFFAOYSA-N 0.000 description 2
- YWEYRKGYCZRIQT-UHFFFAOYSA-N CC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC(CF)=C(F)C=C3)=CC=C2)COC1 Chemical compound CC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC(CF)=C(F)C=C3)=CC=C2)COC1 YWEYRKGYCZRIQT-UHFFFAOYSA-N 0.000 description 2
- WRLPUUWILVEMQQ-UHFFFAOYSA-N CC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC(CO)=C(F)C=C3)=CC=C2)COC1 Chemical compound CC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC(CO)=C(F)C=C3)=CC=C2)COC1 WRLPUUWILVEMQQ-UHFFFAOYSA-N 0.000 description 2
- OXZBKQPDJGQEID-UHFFFAOYSA-N CC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC=C(F)C=C3)=CC=C2)COC1 Chemical compound CC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC=C(F)C=C3)=CC=C2)COC1 OXZBKQPDJGQEID-UHFFFAOYSA-N 0.000 description 2
- GKHBIBICPITFSB-UHFFFAOYSA-N CC1(CS(=O)(=O)C2=CC=C(Br)C(C(=O)NC3=CC=C(F)C(C#N)=C3)=C2F)COC1 Chemical compound CC1(CS(=O)(=O)C2=CC=C(Br)C(C(=O)NC3=CC=C(F)C(C#N)=C3)=C2F)COC1 GKHBIBICPITFSB-UHFFFAOYSA-N 0.000 description 2
- MCNUPFTZKNKNBL-UHFFFAOYSA-N CC1(CS(=O)(=O)C2=CC=C(Br)C(C(=O)NC3=CC=C(F)C(C(F)(F)F)=C3)=C2F)COC1 Chemical compound CC1(CS(=O)(=O)C2=CC=C(Br)C(C(=O)NC3=CC=C(F)C(C(F)(F)F)=C3)=C2F)COC1 MCNUPFTZKNKNBL-UHFFFAOYSA-N 0.000 description 2
- ZSFUQUUWGHKCCL-UHFFFAOYSA-N CC1(CS(=O)(=O)C2=CC=C(Cl)C(C(=O)NC3=CC=C(F)C(C(F)(F)F)=C3)=C2)COC1 Chemical compound CC1(CS(=O)(=O)C2=CC=C(Cl)C(C(=O)NC3=CC=C(F)C(C(F)(F)F)=C3)=C2)COC1 ZSFUQUUWGHKCCL-UHFFFAOYSA-N 0.000 description 2
- WLEUWRZCUFLAHU-UHFFFAOYSA-N CC1(CS(=O)(=O)C2=CC=C(Cl)C(C(=O)NC3=CC=C(F)C(F)=C3)=C2)COC1 Chemical compound CC1(CS(=O)(=O)C2=CC=C(Cl)C(C(=O)NC3=CC=C(F)C(F)=C3)=C2)COC1 WLEUWRZCUFLAHU-UHFFFAOYSA-N 0.000 description 2
- KTMOUIPMUOPLJG-UHFFFAOYSA-N CC1(CS(=O)(=O)C2=CC=C(F)C(C(=O)NC3=CC=C(F)C(C(F)(F)F)=C3)=C2Br)COC1 Chemical compound CC1(CS(=O)(=O)C2=CC=C(F)C(C(=O)NC3=CC=C(F)C(C(F)(F)F)=C3)=C2Br)COC1 KTMOUIPMUOPLJG-UHFFFAOYSA-N 0.000 description 2
- KJBLIMIWNLPQTG-UHFFFAOYSA-N CC1(CS(=O)(=O)C2=CC=C(F)C(C(=O)NC3=CC=C(F)C(F)=C3)=C2Cl)COC1 Chemical compound CC1(CS(=O)(=O)C2=CC=C(F)C(C(=O)NC3=CC=C(F)C(F)=C3)=C2Cl)COC1 KJBLIMIWNLPQTG-UHFFFAOYSA-N 0.000 description 2
- OJUDRVJFJUTZIO-UHFFFAOYSA-N CC1(CS(=O)(=O)C2=CC=CC(C(=O)NC3=CC=C(F)C=C3)=C2)CCCC1 Chemical compound CC1(CS(=O)(=O)C2=CC=CC(C(=O)NC3=CC=C(F)C=C3)=C2)CCCC1 OJUDRVJFJUTZIO-UHFFFAOYSA-N 0.000 description 2
- RTXCHPWBSUZJDQ-UHFFFAOYSA-N CC1(CS(=O)(=O)C2=CC=CC(C(=O)NC3=CC=C(F)C=C3)=C2)CCOCC1 Chemical compound CC1(CS(=O)(=O)C2=CC=CC(C(=O)NC3=CC=C(F)C=C3)=C2)CCOCC1 RTXCHPWBSUZJDQ-UHFFFAOYSA-N 0.000 description 2
- KSNCARBRRBBULX-UHFFFAOYSA-N CC1(NS(=O)(=O)C2=C(F)C(C(=O)CC3=CC=C(F)C(C(F)(F)F)=C3)=CC=C2)COC1 Chemical compound CC1(NS(=O)(=O)C2=C(F)C(C(=O)CC3=CC=C(F)C(C(F)(F)F)=C3)=CC=C2)COC1 KSNCARBRRBBULX-UHFFFAOYSA-N 0.000 description 2
- MOBINXYHXYDJFL-UHFFFAOYSA-N CC1(NS(=O)(=O)C2=C(F)C(C(=O)CC3=CC=C(F)C(C(F)F)=C3)=CC(Cl)=C2)COC1 Chemical compound CC1(NS(=O)(=O)C2=C(F)C(C(=O)CC3=CC=C(F)C(C(F)F)=C3)=CC(Cl)=C2)COC1 MOBINXYHXYDJFL-UHFFFAOYSA-N 0.000 description 2
- VTLDGGWIHCSBFN-UHFFFAOYSA-N CC1(NS(=O)(=O)C2=C(F)C(C(=O)CC3=CC=C(F)C(C(F)F)=C3)=CC=C2)COC1 Chemical compound CC1(NS(=O)(=O)C2=C(F)C(C(=O)CC3=CC=C(F)C(C(F)F)=C3)=CC=C2)COC1 VTLDGGWIHCSBFN-UHFFFAOYSA-N 0.000 description 2
- AGVKMAZUTDLGCN-UHFFFAOYSA-N CC1(NS(=O)(=O)C2=C(F)C(C(=O)NC3=CC=C(F)C(C#N)=C3)=C(Cl)C=C2)COC1 Chemical compound CC1(NS(=O)(=O)C2=C(F)C(C(=O)NC3=CC=C(F)C(C#N)=C3)=C(Cl)C=C2)COC1 AGVKMAZUTDLGCN-UHFFFAOYSA-N 0.000 description 2
- LWXUUZLPFVBLRU-UHFFFAOYSA-N CC1(NS(=O)(=O)C2=C(F)C(C(=O)NC3=CC=C(F)C(C(F)(F)F)=C3)=C(Cl)C=C2)COC1 Chemical compound CC1(NS(=O)(=O)C2=C(F)C(C(=O)NC3=CC=C(F)C(C(F)(F)F)=C3)=C(Cl)C=C2)COC1 LWXUUZLPFVBLRU-UHFFFAOYSA-N 0.000 description 2
- DJBVRBRUVGBQFS-UHFFFAOYSA-N CC1(NS(=O)(=O)C2=CC=C(Cl)C(C(=O)NC3=CC=C(F)C(C(F)F)=C3)=C2)CCC1 Chemical compound CC1(NS(=O)(=O)C2=CC=C(Cl)C(C(=O)NC3=CC=C(F)C(C(F)F)=C3)=C2)CCC1 DJBVRBRUVGBQFS-UHFFFAOYSA-N 0.000 description 2
- URPFWESKVGDUKM-MERQFXBCSA-N CC1=C(Br)C=C(S(=O)(=O)N[C@H]2CCOC2)C(F)=C1C(=O)NC1=CC=C(F)C(F)=C1.S Chemical compound CC1=C(Br)C=C(S(=O)(=O)N[C@H]2CCOC2)C(F)=C1C(=O)NC1=CC=C(F)C(F)=C1.S URPFWESKVGDUKM-MERQFXBCSA-N 0.000 description 2
- PDLWAIAVDWMPQA-UHFFFAOYSA-N CC1=C(C#N)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCCC3)=C2)=C1 Chemical compound CC1=C(C#N)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCCC3)=C2)=C1 PDLWAIAVDWMPQA-UHFFFAOYSA-N 0.000 description 2
- KJNYMRUARQJANC-UHFFFAOYSA-N CC1=C(C)C(NC(=O)C2=CC=CC(S(=O)(=O)CC3(C)COC3)=C2)=CC=C1F Chemical compound CC1=C(C)C(NC(=O)C2=CC=CC(S(=O)(=O)CC3(C)COC3)=C2)=CC=C1F KJNYMRUARQJANC-UHFFFAOYSA-N 0.000 description 2
- NEHIVPKWFXLHFN-UHFFFAOYSA-N CC1=C(F)C(F)=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C)=C2)=C1 Chemical compound CC1=C(F)C(F)=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C)=C2)=C1 NEHIVPKWFXLHFN-UHFFFAOYSA-N 0.000 description 2
- SLIARNNYUXXLFX-ZOWNYOTGSA-N CC1=C(F)C=C(F)C(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)=C1.S Chemical compound CC1=C(F)C=C(F)C(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)=C1.S SLIARNNYUXXLFX-ZOWNYOTGSA-N 0.000 description 2
- PNHDJEJKZSLUBB-ZOWNYOTGSA-N CC1=C(F)C=CC(NC(=O)C2=C(C(F)(F)F)C=CC(S(=O)(=O)N[C@H]3CCOC3)=C2)=C1.S Chemical compound CC1=C(F)C=CC(NC(=O)C2=C(C(F)(F)F)C=CC(S(=O)(=O)N[C@H]3CCOC3)=C2)=C1.S PNHDJEJKZSLUBB-ZOWNYOTGSA-N 0.000 description 2
- UVKNPAKYKLEYMZ-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=C(C)C=CC(S(=O)(=O)CC3(C)COC3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=C(C)C=CC(S(=O)(=O)CC3(C)COC3)=C2)=C1 UVKNPAKYKLEYMZ-UHFFFAOYSA-N 0.000 description 2
- AWVTUBSWZNSRAO-MERQFXBCSA-N CC1=C(F)C=CC(NC(=O)C2=CC(S(=O)(=O)N[C@@H](C)C(F)(F)F)=CC=C2)=C1.S Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC(S(=O)(=O)N[C@@H](C)C(F)(F)F)=CC=C2)=C1.S AWVTUBSWZNSRAO-MERQFXBCSA-N 0.000 description 2
- MKMZOTNAYSOFHK-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C)=C2)=C1 MKMZOTNAYSOFHK-UHFFFAOYSA-N 0.000 description 2
- GZLAKTLQQUPIBL-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C3=CC=NC=C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C3=CC=NC=C3)=C2)=C1 GZLAKTLQQUPIBL-UHFFFAOYSA-N 0.000 description 2
- QSAIHAVDQJHTKS-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C3=CN=CC=C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C3=CN=CC=C3)=C2)=C1 QSAIHAVDQJHTKS-UHFFFAOYSA-N 0.000 description 2
- YLKQFQAJBUKSRC-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C3=NC=CC=C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C3=NC=CC=C3)=C2)=C1 YLKQFQAJBUKSRC-UHFFFAOYSA-N 0.000 description 2
- HRVSOSOWLNQDOF-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C3CCN(C)CC3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C3CCN(C)CC3)=C2)=C1 HRVSOSOWLNQDOF-UHFFFAOYSA-N 0.000 description 2
- MLVYLWLHCRPKFT-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)CC3=CC=NC=C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)CC3=CC=NC=C3)=C2)=C1 MLVYLWLHCRPKFT-UHFFFAOYSA-N 0.000 description 2
- LETSAZGYJIOXFN-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)CCC3=CC=CC=C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)CCC3=CC=CC=C3)=C2)=C1 LETSAZGYJIOXFN-UHFFFAOYSA-N 0.000 description 2
- SFGBWRFKXJFKGS-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)CN3CCN(C)CC3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)CN3CCN(C)CC3)=C2)=C1 SFGBWRFKXJFKGS-UHFFFAOYSA-N 0.000 description 2
- BACXLNHVLPBFSX-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)CN3CCOCC3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)CN3CCOCC3)=C2)=C1 BACXLNHVLPBFSX-UHFFFAOYSA-N 0.000 description 2
- HFZKUZCNONNRJL-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CC(O)C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CC(O)C3)=C2)=C1 HFZKUZCNONNRJL-UHFFFAOYSA-N 0.000 description 2
- JLZSHWKOVDUVHX-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CC4=C(C=CC=C4)C3O)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CC4=C(C=CC=C4)C3O)=C2)=C1 JLZSHWKOVDUVHX-UHFFFAOYSA-N 0.000 description 2
- AXFZVFPWTZFRNK-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCC(F)(F)C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCC(F)(F)C3)=C2)=C1 AXFZVFPWTZFRNK-UHFFFAOYSA-N 0.000 description 2
- DKOOROGTYNDWNM-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCC(F)(F)CC3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCC(F)(F)CC3)=C2)=C1 DKOOROGTYNDWNM-UHFFFAOYSA-N 0.000 description 2
- MSQMAXVDCSPSAQ-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCC(O)C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCC(O)C3)=C2)=C1 MSQMAXVDCSPSAQ-UHFFFAOYSA-N 0.000 description 2
- KRWXDHHIBCHIBK-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCCC(O)C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCCC(O)C3)=C2)=C1 KRWXDHHIBCHIBK-UHFFFAOYSA-N 0.000 description 2
- KRNYZNHQXKXJME-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCCN(C(=O)OC(C)(C)C)C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCCN(C(=O)OC(C)(C)C)C3)=C2)=C1 KRNYZNHQXKXJME-UHFFFAOYSA-N 0.000 description 2
- FJLPAAQLTDRTMF-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCN(C(=O)OC(C)(C)C)C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCN(C(=O)OC(C)(C)C)C3)=C2)=C1 FJLPAAQLTDRTMF-UHFFFAOYSA-N 0.000 description 2
- VWYTYFLYRDALIN-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCS(=O)(=O)C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCS(=O)(=O)C3)=C2)=C1 VWYTYFLYRDALIN-UHFFFAOYSA-N 0.000 description 2
- XNIYHDLEDURFNA-XFULWGLBSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H](C)C(C)C)=C2)=C1.S Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H](C)C(C)C)=C2)=C1.S XNIYHDLEDURFNA-XFULWGLBSA-N 0.000 description 2
- MFRVWUHFNRECIJ-PFEQFJNWSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H](C)C3CC3)=C2)=C1.S Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H](C)C3CC3)=C2)=C1.S MFRVWUHFNRECIJ-PFEQFJNWSA-N 0.000 description 2
- RANXCUGULCLMHR-UNTBIKODSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H](C)C3CCCCC3)=C2)=C1.S Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H](C)C3CCCCC3)=C2)=C1.S RANXCUGULCLMHR-UNTBIKODSA-N 0.000 description 2
- QYBWMXXSKQUIBW-JXFKEZNVSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCCC[C@@H]3O)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCCC[C@@H]3O)=C2)=C1 QYBWMXXSKQUIBW-JXFKEZNVSA-N 0.000 description 2
- QYBWMXXSKQUIBW-OXJNMPFZSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCCC[C@H]3O)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCCC[C@H]3O)=C2)=C1 QYBWMXXSKQUIBW-OXJNMPFZSA-N 0.000 description 2
- JAHPPGSBAXBMHZ-XQDURQLCSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCCC[C@@H]3O)=C2)=C1.S.S Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCCC[C@@H]3O)=C2)=C1.S.S JAHPPGSBAXBMHZ-XQDURQLCSA-N 0.000 description 2
- MXFNFQVOFYSXDU-HOOCCGKBSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCC[C@@H]3O)=C2)=C1.S.S Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCC[C@@H]3O)=C2)=C1.S.S MXFNFQVOFYSXDU-HOOCCGKBSA-N 0.000 description 2
- ASWFCKLBPPIBFO-ZOWNYOTGSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)=C1F.S Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)=C1F.S ASWFCKLBPPIBFO-ZOWNYOTGSA-N 0.000 description 2
- XFLFSCTVDNTUCV-RZDIXWSQSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CC[C@H](O)CC3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CC[C@H](O)CC3)=C2)=C1 XFLFSCTVDNTUCV-RZDIXWSQSA-N 0.000 description 2
- HFZKUZCNONNRJL-AKAXFMLLSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3C[C@@H](O)C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3C[C@@H](O)C3)=C2)=C1 HFZKUZCNONNRJL-AKAXFMLLSA-N 0.000 description 2
- HFZKUZCNONNRJL-SAZUREKKSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3C[C@H](O)C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3C[C@H](O)C3)=C2)=C1 HFZKUZCNONNRJL-SAZUREKKSA-N 0.000 description 2
- ZMKZVPMEFBWIID-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)N3CC4(CCOC4)C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)N3CC4(CCOC4)C3)=C2)=C1 ZMKZVPMEFBWIID-UHFFFAOYSA-N 0.000 description 2
- WBKYGVMFCAYAAF-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)N3CC4(COC4)C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)N3CC4(COC4)C3)=C2)=C1 WBKYGVMFCAYAAF-UHFFFAOYSA-N 0.000 description 2
- BZPZXJMBSSWPNK-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)N3CCC34COC4)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)N3CCC34COC4)=C2)=C1 BZPZXJMBSSWPNK-UHFFFAOYSA-N 0.000 description 2
- AEDXNLAVWHQAJX-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)NC3(C)COC3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)NC3(C)COC3)=C2)=C1 AEDXNLAVWHQAJX-UHFFFAOYSA-N 0.000 description 2
- PFFOJAZUSPSYPQ-ZOWNYOTGSA-N CC1=C(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)C=CC(F)=C1F.S Chemical compound CC1=C(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)C=CC(F)=C1F.S PFFOJAZUSPSYPQ-ZOWNYOTGSA-N 0.000 description 2
- PQQXXKVYKFFLSV-UHFFFAOYSA-N CC1=CC(CC(=O)C2=CC(S(=O)(=O)NC(C)C)=CC(F)=C2)=CC=C1F Chemical compound CC1=CC(CC(=O)C2=CC(S(=O)(=O)NC(C)C)=CC(F)=C2)=CC=C1F PQQXXKVYKFFLSV-UHFFFAOYSA-N 0.000 description 2
- RSRUWLIICQZOCP-NTISSMGPSA-N CC1=CC(CC(=O)C2=CC(S(=O)(=O)N[C@H]3CCOC3)=CC(F)=C2)=CC=C1F.S Chemical compound CC1=CC(CC(=O)C2=CC(S(=O)(=O)N[C@H]3CCOC3)=CC(F)=C2)=CC=C1F.S RSRUWLIICQZOCP-NTISSMGPSA-N 0.000 description 2
- ZJWMHTMECCZKRK-UHFFFAOYSA-N CC1=CC(CC(=O)C2=CC=CC(S(=O)(=O)NC(C)(C)C)=C2F)=CC=C1F Chemical compound CC1=CC(CC(=O)C2=CC=CC(S(=O)(=O)NC(C)(C)C)=C2F)=CC=C1F ZJWMHTMECCZKRK-UHFFFAOYSA-N 0.000 description 2
- OHLZTHRPUCSRRO-UHFFFAOYSA-N CC1=CC(F)=C(C)C=C1NC(=O)C1=CC=CC(S(=O)(=O)CC2(C)COC2)=C1 Chemical compound CC1=CC(F)=C(C)C=C1NC(=O)C1=CC=CC(S(=O)(=O)CC2(C)COC2)=C1 OHLZTHRPUCSRRO-UHFFFAOYSA-N 0.000 description 2
- UTLRAKBHEOFUKF-UHFFFAOYSA-N CC1=CC(F)=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCCC3)=C2)=C1 Chemical compound CC1=CC(F)=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCCC3)=C2)=C1 UTLRAKBHEOFUKF-UHFFFAOYSA-N 0.000 description 2
- UAYOYNDKHKQZPH-RSAXXLAASA-N CC1=CC(NC(=O)C2=C(C)C=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)=CC=C1F.S Chemical compound CC1=CC(NC(=O)C2=C(C)C=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)=CC=C1F.S UAYOYNDKHKQZPH-RSAXXLAASA-N 0.000 description 2
- FRYJPYJYERXVPB-UHFFFAOYSA-N CC1=CC(NC(=O)C2=C(C)OC(S(=O)(=O)NC(C)C)=C2)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=C(C)OC(S(=O)(=O)NC(C)C)=C2)=CC=C1F FRYJPYJYERXVPB-UHFFFAOYSA-N 0.000 description 2
- JVNWNPXGCULDEM-YDALLXLXSA-N CC1=CC(NC(=O)C2=C(Cl)C=CC(S(=O)(=O)C[C@H]3CCOC3)=C2Cl)=CC=C1F.S Chemical compound CC1=CC(NC(=O)C2=C(Cl)C=CC(S(=O)(=O)C[C@H]3CCOC3)=C2Cl)=CC=C1F.S JVNWNPXGCULDEM-YDALLXLXSA-N 0.000 description 2
- AEARVOGZEOZYJJ-UHFFFAOYSA-N CC1=CC(NC(=O)C2=C(Cl)C=CC(S(=O)(=O)NC3(C)COC3)=C2F)=CC(F)=C1F Chemical compound CC1=CC(NC(=O)C2=C(Cl)C=CC(S(=O)(=O)NC3(C)COC3)=C2F)=CC(F)=C1F AEARVOGZEOZYJJ-UHFFFAOYSA-N 0.000 description 2
- ZJKLCIFXHGGTHW-UHFFFAOYSA-N CC1=CC(NC(=O)C2=C(F)C(S(=O)(=O)CC3(C)COC3)=CC=C2Br)=CC(F)=C1F Chemical compound CC1=CC(NC(=O)C2=C(F)C(S(=O)(=O)CC3(C)COC3)=CC=C2Br)=CC(F)=C1F ZJKLCIFXHGGTHW-UHFFFAOYSA-N 0.000 description 2
- NLNLTRFGFKSCOW-UHFFFAOYSA-N CC1=CC(NC(=O)C2=C(F)C(S(=O)(=O)CC3(C)COC3)=CC=C2Br)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=C(F)C(S(=O)(=O)CC3(C)COC3)=CC=C2Br)=CC=C1F NLNLTRFGFKSCOW-UHFFFAOYSA-N 0.000 description 2
- JGTRDIJZFLBWAA-UHFFFAOYSA-N CC1=CC(NC(=O)C2=C(F)C(S(=O)(=O)NC(C)(C)C)=CC=C2C)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=C(F)C(S(=O)(=O)NC(C)(C)C)=CC=C2C)=CC=C1F JGTRDIJZFLBWAA-UHFFFAOYSA-N 0.000 description 2
- XXGNFTGLZATNQE-UHFFFAOYSA-N CC1=CC(NC(=O)C2=C(F)C(S(=O)(=O)NC3(C)COC3)=CC(Br)=C2C)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=C(F)C(S(=O)(=O)NC3(C)COC3)=CC(Br)=C2C)=CC=C1F XXGNFTGLZATNQE-UHFFFAOYSA-N 0.000 description 2
- KKHOMTBEYYQLOX-UQKRIMTDSA-N CC1=CC(NC(=O)C2=C(F)C(S(=O)(=O)N[C@H]3CCOC3)=CC=C2C)=CC=C1F.S Chemical compound CC1=CC(NC(=O)C2=C(F)C(S(=O)(=O)N[C@H]3CCOC3)=CC=C2C)=CC=C1F.S KKHOMTBEYYQLOX-UQKRIMTDSA-N 0.000 description 2
- PXDOAHSMRKTXPR-YDALLXLXSA-N CC1=CC(NC(=O)C2=CC(Cl)=CC(S(=O)(=O)C[C@H]3CCOC3)=C2F)=CC=C1F.S Chemical compound CC1=CC(NC(=O)C2=CC(Cl)=CC(S(=O)(=O)C[C@H]3CCOC3)=C2F)=CC=C1F.S PXDOAHSMRKTXPR-YDALLXLXSA-N 0.000 description 2
- FFSRPHPITGASOV-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC(C)CC3=CC=CC=C3)=CC=C2)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC(C)CC3=CC=CC=C3)=CC=C2)=CC=C1F FFSRPHPITGASOV-UHFFFAOYSA-N 0.000 description 2
- YAXXOZYTAWFVMV-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC(C)CCN3CCOCC3)=CC=C2)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC(C)CCN3CCOCC3)=CC=C2)=CC=C1F YAXXOZYTAWFVMV-UHFFFAOYSA-N 0.000 description 2
- DPORRBMPLOPASL-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3(C)COC3)=CC=C2Cl)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3(C)COC3)=CC=C2Cl)=CC=C1F DPORRBMPLOPASL-UHFFFAOYSA-N 0.000 description 2
- XFWJYYOQLVAVNU-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3CC4=CC=CC=C4C3)=CC=C2)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3CC4=CC=CC=C4C3)=CC=C2)=CC=C1F XFWJYYOQLVAVNU-UHFFFAOYSA-N 0.000 description 2
- BHYBAZLWDGCXGR-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3CCCC3)=CC=C2)=CC(C#N)=C1 Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3CCCC3)=CC=C2)=CC(C#N)=C1 BHYBAZLWDGCXGR-UHFFFAOYSA-N 0.000 description 2
- UUBDGSLSEKUYNE-UNTBIKODSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)C[C@@H](C)C3=CC=CC=C3)=CC=C2)=CC=C1F.S Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)C[C@@H](C)C3=CC=CC=C3)=CC=C2)=CC=C1F.S UUBDGSLSEKUYNE-UNTBIKODSA-N 0.000 description 2
- LJVLXLLXTFMKJP-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)N3CCCCC3)=C(Cl)C=C2Cl)=CC=C1 Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)N3CCCCC3)=C(Cl)C=C2Cl)=CC=C1 LJVLXLLXTFMKJP-UHFFFAOYSA-N 0.000 description 2
- HAILBIPNVXAIAH-ZOWNYOTGSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)N[C@H]3CCOC3)=CC=C2Br)=CC=C1F.S Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)N[C@H]3CCOC3)=CC=C2Br)=CC=C1F.S HAILBIPNVXAIAH-ZOWNYOTGSA-N 0.000 description 2
- ZNPCMZQOGGYJRZ-ZOWNYOTGSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)N[C@H]3CCOC3)=CC=C2F)=CC=C1F.S Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)N[C@H]3CCOC3)=CC=C2F)=CC=C1F.S ZNPCMZQOGGYJRZ-ZOWNYOTGSA-N 0.000 description 2
- OZWQGPZYTBKWCN-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC=C(S(=O)(=O)NC3(C)COC3)O2)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=CC=C(S(=O)(=O)NC3(C)COC3)O2)=CC=C1F OZWQGPZYTBKWCN-UHFFFAOYSA-N 0.000 description 2
- WAKGHTZRNNVDCP-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3(C)CCOC3)=C2)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3(C)CCOC3)=C2)=CC=C1F WAKGHTZRNNVDCP-UHFFFAOYSA-N 0.000 description 2
- XZJCHBCPRJNOQU-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3(C)COC3)=C2F)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3(C)COC3)=C2F)=CC=C1F XZJCHBCPRJNOQU-UHFFFAOYSA-N 0.000 description 2
- OKLDLNAZXGDVGU-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CC4CCC3O4)=C2)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CC4CCC3O4)=C2)=CC=C1F OKLDLNAZXGDVGU-UHFFFAOYSA-N 0.000 description 2
- LNYRXBGJYVEXHU-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCCC3)=C2)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCCC3)=C2)=CC=C1F LNYRXBGJYVEXHU-UHFFFAOYSA-N 0.000 description 2
- UTHIIMUAIGJZRC-UQKRIMTDSA-N CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)=CC=C1F.S Chemical compound CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)=CC=C1F.S UTHIIMUAIGJZRC-UQKRIMTDSA-N 0.000 description 2
- GNICCVHPNPGAND-RSAXXLAASA-N CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2C)=CC=C1F.S Chemical compound CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2C)=CC=C1F.S GNICCVHPNPGAND-RSAXXLAASA-N 0.000 description 2
- CVSYGURRPJZDLZ-ZOWNYOTGSA-N CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2Cl)=CC=C1F.S Chemical compound CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2Cl)=CC=C1F.S CVSYGURRPJZDLZ-ZOWNYOTGSA-N 0.000 description 2
- LYYBDPOUGGFFBS-UHFFFAOYSA-N CC1=CC=C(NC(=O)C2=CC(S(=O)(=O)CC3CCCC3)=CC=C2)C=C1F Chemical compound CC1=CC=C(NC(=O)C2=CC(S(=O)(=O)CC3CCCC3)=CC=C2)C=C1F LYYBDPOUGGFFBS-UHFFFAOYSA-N 0.000 description 2
- WPKKRTOZRBBOPK-UHFFFAOYSA-N CC1=CC=C(S(=O)(=O)CC2(C)COC2)C=C1C(=O)NC1=CC(C(F)F)=C(F)C=C1 Chemical compound CC1=CC=C(S(=O)(=O)CC2(C)COC2)C=C1C(=O)NC1=CC(C(F)F)=C(F)C=C1 WPKKRTOZRBBOPK-UHFFFAOYSA-N 0.000 description 2
- NSPPLHFENDVIPV-UHFFFAOYSA-N CC1=CC=C(S(=O)(=O)CC2(C)COC2)C=C1C(=O)NC1=CC=C(F)C(C(F)(F)F)=C1 Chemical compound CC1=CC=C(S(=O)(=O)CC2(C)COC2)C=C1C(=O)NC1=CC=C(F)C(C(F)(F)F)=C1 NSPPLHFENDVIPV-UHFFFAOYSA-N 0.000 description 2
- CRDWXRQCOAPOQF-UHFFFAOYSA-N CC1=CC=C(S(=O)(=O)NC(C)(C)C)C(F)=C1C(=O)NC1=CC=C(F)C(F)=C1 Chemical compound CC1=CC=C(S(=O)(=O)NC(C)(C)C)C(F)=C1C(=O)NC1=CC=C(F)C(F)=C1 CRDWXRQCOAPOQF-UHFFFAOYSA-N 0.000 description 2
- WUPGUVUDQVCSNX-UHFFFAOYSA-N CC1=CC=C(S(=O)(=O)NC2(C)COC2)C(F)=C1C(=O)NC1=CC(Cl)=C(F)C(F)=C1 Chemical compound CC1=CC=C(S(=O)(=O)NC2(C)COC2)C(F)=C1C(=O)NC1=CC(Cl)=C(F)C(F)=C1 WUPGUVUDQVCSNX-UHFFFAOYSA-N 0.000 description 2
- YFDPUCYJSNBFSU-UHFFFAOYSA-N CC1=CC=C(S(=O)(=O)NC2(C)COC2)C(F)=C1C(=O)NC1=CC=C(F)C(C#N)=C1 Chemical compound CC1=CC=C(S(=O)(=O)NC2(C)COC2)C(F)=C1C(=O)NC1=CC=C(F)C(C#N)=C1 YFDPUCYJSNBFSU-UHFFFAOYSA-N 0.000 description 2
- UYUNXJCWRYEVRH-UHFFFAOYSA-N CC1=CC=C(S(=O)(=O)NC2(C)COC2)C(F)=C1C(=O)NC1=CC=C(F)C(Cl)=C1 Chemical compound CC1=CC=C(S(=O)(=O)NC2(C)COC2)C(F)=C1C(=O)NC1=CC=C(F)C(Cl)=C1 UYUNXJCWRYEVRH-UHFFFAOYSA-N 0.000 description 2
- OXMVQWJKNWXFKW-UHFFFAOYSA-N CC1=CC=C(S(=O)(=O)NC2(C)COC2)C(F)=C1C(=O)NC1=CC=C(F)C(F)=C1 Chemical compound CC1=CC=C(S(=O)(=O)NC2(C)COC2)C(F)=C1C(=O)NC1=CC=C(F)C(F)=C1 OXMVQWJKNWXFKW-UHFFFAOYSA-N 0.000 description 2
- BDOXUNOBOFVRGD-YDALLXLXSA-N CC1=CC=C(S(=O)(=O)N[C@H]2CCOC2)C(F)=C1C(=O)NC1=CC=C(F)C(F)=C1.S Chemical compound CC1=CC=C(S(=O)(=O)N[C@H]2CCOC2)C(F)=C1C(=O)NC1=CC=C(F)C(F)=C1.S BDOXUNOBOFVRGD-YDALLXLXSA-N 0.000 description 2
- XFFKBCPHQPSMKY-UHFFFAOYSA-N CC1=CC=CC(CC(=O)C2=CC(S(=O)(=O)CC3CCCCC3)=CC=C2F)=C1 Chemical compound CC1=CC=CC(CC(=O)C2=CC(S(=O)(=O)CC3CCCCC3)=CC=C2F)=C1 XFFKBCPHQPSMKY-UHFFFAOYSA-N 0.000 description 2
- XPYVGBCHXWFNQV-UHFFFAOYSA-N CCC(C)(C)CS(=O)(=O)C1=CC=CC(C(=O)NC2=CC=C(F)C=C2)=C1 Chemical compound CCC(C)(C)CS(=O)(=O)C1=CC=CC(C(=O)NC2=CC=C(F)C=C2)=C1 XPYVGBCHXWFNQV-UHFFFAOYSA-N 0.000 description 2
- WJISDJYKRANTJA-UHFFFAOYSA-N CCC(CC)CS(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C=C2)=CC=C1 Chemical compound CCC(CC)CS(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C=C2)=CC=C1 WJISDJYKRANTJA-UHFFFAOYSA-N 0.000 description 2
- GWNNXALGPHTTKK-UHFFFAOYSA-N CCC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC(C)=C(F)C=C3)=CC=C2)COC1 Chemical compound CCC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC(C)=C(F)C=C3)=CC=C2)COC1 GWNNXALGPHTTKK-UHFFFAOYSA-N 0.000 description 2
- NCAUMHFDWNRFNY-UHFFFAOYSA-N CCC1(NS(=O)(=O)C2=CC=CC(C(=O)NC3=CC=C(F)C=C3)=C2)COC1 Chemical compound CCC1(NS(=O)(=O)C2=CC=CC(C(=O)NC3=CC=C(F)C=C3)=C2)COC1 NCAUMHFDWNRFNY-UHFFFAOYSA-N 0.000 description 2
- OLWARFDNTHZSHX-UHFFFAOYSA-N CCC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C)=C2)=C1 Chemical compound CCC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C)=C2)=C1 OLWARFDNTHZSHX-UHFFFAOYSA-N 0.000 description 2
- GEIRWMQRGJDRGP-ZOWNYOTGSA-N CC[C@H](C)CS(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C=C2)=CC=C1.S Chemical compound CC[C@H](C)CS(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C=C2)=CC=C1.S GEIRWMQRGJDRGP-ZOWNYOTGSA-N 0.000 description 2
- UAOMGOLIUPXPPU-UHFFFAOYSA-N CN(C(=O)C1CCCCC1)S(=O)(=O)C1=CC=CC(C(=O)CC2=CC=C(F)C=C2)=C1 Chemical compound CN(C(=O)C1CCCCC1)S(=O)(=O)C1=CC=CC(C(=O)CC2=CC=C(F)C=C2)=C1 UAOMGOLIUPXPPU-UHFFFAOYSA-N 0.000 description 2
- RLNYDZCHMZBCSB-UHFFFAOYSA-N CN(C)S(=O)(=O)C1=CC(C(=O)NC2=CC=CC=C2)=C(F)C=C1 Chemical compound CN(C)S(=O)(=O)C1=CC(C(=O)NC2=CC=CC=C2)=C(F)C=C1 RLNYDZCHMZBCSB-UHFFFAOYSA-N 0.000 description 2
- KSZHGMXADUPLBH-UHFFFAOYSA-N CN(C1CCCC1)S(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C=C2)=CC=C1 Chemical compound CN(C1CCCC1)S(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C=C2)=CC=C1 KSZHGMXADUPLBH-UHFFFAOYSA-N 0.000 description 2
- DWPJPWPLAOZMBR-UHFFFAOYSA-N CN1CCN(S(=O)(=O)C2=CC(C(=O)NC3=CC=C(F)C=C3)=CC=C2)CC1 Chemical compound CN1CCN(S(=O)(=O)C2=CC(C(=O)NC3=CC=C(F)C=C3)=CC=C2)CC1 DWPJPWPLAOZMBR-UHFFFAOYSA-N 0.000 description 2
- WAMFXOXLBFWSMD-UHFFFAOYSA-N COC(=O)N1CC(C)(CS(=O)(=O)C2=CC(C(=O)NC3=CC(C)=C(F)C=C3)=CC=C2)C1 Chemical compound COC(=O)N1CC(C)(CS(=O)(=O)C2=CC(C(=O)NC3=CC(C)=C(F)C=C3)=CC=C2)C1 WAMFXOXLBFWSMD-UHFFFAOYSA-N 0.000 description 2
- ZXSILDSUUKRSIH-UHFFFAOYSA-N COC(=O)N1CC(CS(=O)(=O)C2=CC(C(=O)NC3=CC(C)=C(F)C=C3)=CC=C2)C1 Chemical compound COC(=O)N1CC(CS(=O)(=O)C2=CC(C(=O)NC3=CC(C)=C(F)C=C3)=CC=C2)C1 ZXSILDSUUKRSIH-UHFFFAOYSA-N 0.000 description 2
- BIRICATZMRGRSH-UHFFFAOYSA-N COC(=O)N1CCC(CS(=O)(=O)C2=CC(C(=O)NC3=CC(C)=C(F)C=C3)=CC=C2)C1 Chemical compound COC(=O)N1CCC(CS(=O)(=O)C2=CC(C(=O)NC3=CC(C)=C(F)C=C3)=CC=C2)C1 BIRICATZMRGRSH-UHFFFAOYSA-N 0.000 description 2
- JTZIJMYFQVFGFH-UHFFFAOYSA-N COC(=O)N1CCCC(CS(=O)(=O)C2=CC(C(=O)NC3=CC(C)=C(F)C=C3)=CC=C2)C1 Chemical compound COC(=O)N1CCCC(CS(=O)(=O)C2=CC(C(=O)NC3=CC(C)=C(F)C=C3)=CC=C2)C1 JTZIJMYFQVFGFH-UHFFFAOYSA-N 0.000 description 2
- KEOQYCVKFPFVSZ-RSAXXLAASA-N COC1=C(C)C=C(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)C=C1.S Chemical compound COC1=C(C)C=C(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)C=C1.S KEOQYCVKFPFVSZ-RSAXXLAASA-N 0.000 description 2
- ZPAXMSHQQJZRFG-UHFFFAOYSA-N COC1=C(F)C=C(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C)=C2)C=C1 Chemical compound COC1=C(F)C=C(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C)=C2)C=C1 ZPAXMSHQQJZRFG-UHFFFAOYSA-N 0.000 description 2
- UNBSCTFSIDAUTK-UHFFFAOYSA-N COC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3(C)COC3)=C2)=C1 Chemical compound COC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3(C)COC3)=C2)=C1 UNBSCTFSIDAUTK-UHFFFAOYSA-N 0.000 description 2
- UGRSVCAUKWKIAR-ZOWNYOTGSA-N COC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)=C1.S Chemical compound COC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)=C1.S UGRSVCAUKWKIAR-ZOWNYOTGSA-N 0.000 description 2
- YSPYOISDRMHZJK-ZOWNYOTGSA-N N#CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)=C1.S Chemical compound N#CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2)=C1.S YSPYOISDRMHZJK-ZOWNYOTGSA-N 0.000 description 2
- VZQWFLPRYNEGCE-UHFFFAOYSA-N N#CC1=CC=C(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCCC3)=C2)C=C1 Chemical compound N#CC1=CC=C(NC(=O)C2=CC=CC(S(=O)(=O)CC3CCCC3)=C2)C=C1 VZQWFLPRYNEGCE-UHFFFAOYSA-N 0.000 description 2
- DTRQQGNANDBBEH-UHFFFAOYSA-N N#CC1=CC=CC(NC(=O)C2=CC(S(=O)(=O)CC3CCCC3)=CC=C2)=C1 Chemical compound N#CC1=CC=CC(NC(=O)C2=CC(S(=O)(=O)CC3CCCC3)=CC=C2)=C1 DTRQQGNANDBBEH-UHFFFAOYSA-N 0.000 description 2
- VHZZXEQLPCJHRP-YDALLXLXSA-N O=C(CC1=CC=C(F)C(C(F)F)=C1)C1=CC=CC(S(=O)(=O)N[C@H]2CCOC2)=C1F.S Chemical compound O=C(CC1=CC=C(F)C(C(F)F)=C1)C1=CC=CC(S(=O)(=O)N[C@H]2CCOC2)=C1F.S VHZZXEQLPCJHRP-YDALLXLXSA-N 0.000 description 2
- QIEPAOYYHGMRPA-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)C1=CC(S(=O)(=O)CC(=O)C2CCCCC2)=CC=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)C1=CC(S(=O)(=O)CC(=O)C2CCCCC2)=CC=C1 QIEPAOYYHGMRPA-UHFFFAOYSA-N 0.000 description 2
- QRCLAZXPJWJJLS-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)C1=CC(S(=O)(=O)N2CCCCC2=O)=CC=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)C1=CC(S(=O)(=O)N2CCCCC2=O)=CC=C1 QRCLAZXPJWJJLS-UHFFFAOYSA-N 0.000 description 2
- BJJTYUPKGGUZDY-UHFFFAOYSA-N O=C(NC1=CC(C(F)(F)F)=CC=C1)C1=CC(S(=O)(=O)CC2CCCC2)=CC=C1 Chemical compound O=C(NC1=CC(C(F)(F)F)=CC=C1)C1=CC(S(=O)(=O)CC2CCCC2)=CC=C1 BJJTYUPKGGUZDY-UHFFFAOYSA-N 0.000 description 2
- CHAYVHKWBRLBDV-YDALLXLXSA-N O=C(NC1=CC(C(F)F)=C(F)C=C1)C1=CC=CC(S(=O)(=O)C[C@H]2CCOC2)=C1.S Chemical compound O=C(NC1=CC(C(F)F)=C(F)C=C1)C1=CC=CC(S(=O)(=O)C[C@H]2CCOC2)=C1.S CHAYVHKWBRLBDV-YDALLXLXSA-N 0.000 description 2
- TWIDJDHALUOUHE-UHFFFAOYSA-N O=C(NC1=CC(Cl)=CC=C1)C1=C(F)C=CC(S(=O)(=O)NC2CCCCC2)=C1 Chemical compound O=C(NC1=CC(Cl)=CC=C1)C1=C(F)C=CC(S(=O)(=O)NC2CCCCC2)=C1 TWIDJDHALUOUHE-UHFFFAOYSA-N 0.000 description 2
- YDAVNRVUJRGAPC-UHFFFAOYSA-N O=C(NC1=CC(F)=C(F)C(F)=C1)C1=C(Cl)C=C(F)C(S(=O)(=O)NC2COCC2O)=C1.O=C(NC1=CC=C(F)C(Cl)=C1)C1=C(Cl)C=C(F)C(S(=O)(=O)NC2COCC2O)=C1 Chemical compound O=C(NC1=CC(F)=C(F)C(F)=C1)C1=C(Cl)C=C(F)C(S(=O)(=O)NC2COCC2O)=C1.O=C(NC1=CC=C(F)C(Cl)=C1)C1=C(Cl)C=C(F)C(S(=O)(=O)NC2COCC2O)=C1 YDAVNRVUJRGAPC-UHFFFAOYSA-N 0.000 description 2
- FYRIFWNEEZVVLN-YDALLXLXSA-N O=C(NC1=CC(F)=C(F)C=C1)C1=CC=CC(S(=O)(=O)C[C@H]2CCOC2)=C1.S Chemical compound O=C(NC1=CC(F)=C(F)C=C1)C1=CC=CC(S(=O)(=O)C[C@H]2CCOC2)=C1.S FYRIFWNEEZVVLN-YDALLXLXSA-N 0.000 description 2
- LNXVVTLUSUEDGW-UHFFFAOYSA-N O=C(NC1=CC(F)=CC(F)=C1)C1=CC(S(=O)(=O)CC2CCCC2)=CC=C1 Chemical compound O=C(NC1=CC(F)=CC(F)=C1)C1=CC(S(=O)(=O)CC2CCCC2)=CC=C1 LNXVVTLUSUEDGW-UHFFFAOYSA-N 0.000 description 2
- PFLINXFIOLZMTG-UHFFFAOYSA-N O=C(NC1=CC(F)=CC=C1)C1=CC(S(=O)(=O)CC2CCCC2)=CC=C1 Chemical compound O=C(NC1=CC(F)=CC=C1)C1=CC(S(=O)(=O)CC2CCCC2)=CC=C1 PFLINXFIOLZMTG-UHFFFAOYSA-N 0.000 description 2
- WXRSFDSOKMFIMR-PPHPATTJSA-N O=C(NC1=CC=C(F)C(Br)=C1)C1=C(F)C=CC(S(=O)(=O)N[C@H]2CCOC2)=C1F.S Chemical compound O=C(NC1=CC=C(F)C(Br)=C1)C1=C(F)C=CC(S(=O)(=O)N[C@H]2CCOC2)=C1F.S WXRSFDSOKMFIMR-PPHPATTJSA-N 0.000 description 2
- VUATWLIXTHEEEI-PPHPATTJSA-N O=C(NC1=CC=C(F)C(Cl)=C1)C1=C(F)C=CC(S(=O)(=O)N[C@H]2CCOC2)=C1F.S Chemical compound O=C(NC1=CC=C(F)C(Cl)=C1)C1=C(F)C=CC(S(=O)(=O)N[C@H]2CCOC2)=C1F.S VUATWLIXTHEEEI-PPHPATTJSA-N 0.000 description 2
- NLJCSOVPDRPREQ-MERQFXBCSA-N O=C(NC1=CC=C(F)C(F)=C1)C1=C(F)C=CC(S(=O)(=O)C[C@H]2CCOC2)=C1.S Chemical compound O=C(NC1=CC=C(F)C(F)=C1)C1=C(F)C=CC(S(=O)(=O)C[C@H]2CCOC2)=C1.S NLJCSOVPDRPREQ-MERQFXBCSA-N 0.000 description 2
- UIDUZDIOWBPHBV-PPHPATTJSA-N O=C(NC1=CC=C(F)C(F)=C1)C1=C(F)C=CC(S(=O)(=O)N[C@H]2CCOC2)=C1F.S Chemical compound O=C(NC1=CC=C(F)C(F)=C1)C1=C(F)C=CC(S(=O)(=O)N[C@H]2CCOC2)=C1F.S UIDUZDIOWBPHBV-PPHPATTJSA-N 0.000 description 2
- ARQNOGMCBSNMSC-UHFFFAOYSA-N O=C(NC1=CC=C(F)C(F)=C1)C1=CC(S(=O)(=O)CC2CCCC2)=CC=C1 Chemical compound O=C(NC1=CC=C(F)C(F)=C1)C1=CC(S(=O)(=O)CC2CCCC2)=CC=C1 ARQNOGMCBSNMSC-UHFFFAOYSA-N 0.000 description 2
- TZODQQRYZLKWDJ-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1=C(F)C=CC(S(=O)(=O)NC2CCCCC2)=C1 Chemical compound O=C(NC1=CC=C(F)C=C1)C1=C(F)C=CC(S(=O)(=O)NC2CCCCC2)=C1 TZODQQRYZLKWDJ-UHFFFAOYSA-N 0.000 description 2
- PPWLWWWWJJZDLC-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)CC2CCC2)=C1 Chemical compound O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)CC2CCC2)=C1 PPWLWWWWJJZDLC-UHFFFAOYSA-N 0.000 description 2
- BMWLQPYLAFJRSY-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)CC2CCCC2)=C1 Chemical compound O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)CC2CCCC2)=C1 BMWLQPYLAFJRSY-UHFFFAOYSA-N 0.000 description 2
- CAUMWDJWLQTICY-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)CC2COC2)=C1 Chemical compound O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)CC2COC2)=C1 CAUMWDJWLQTICY-UHFFFAOYSA-N 0.000 description 2
- SJNLXSQGXUVBAZ-ZOWNYOTGSA-N O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)C[C@H]2CCOC2)=C1.S Chemical compound O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)C[C@H]2CCOC2)=C1.S SJNLXSQGXUVBAZ-ZOWNYOTGSA-N 0.000 description 2
- AWVPLVKPDLPJFH-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)NC2CCCCC2)=C1 Chemical compound O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)NC2CCCCC2)=C1 AWVPLVKPDLPJFH-UHFFFAOYSA-N 0.000 description 2
- QUUFOGAWKGRUMX-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)NC2CCOCC2)=C1 Chemical compound O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)NC2CCOCC2)=C1 QUUFOGAWKGRUMX-UHFFFAOYSA-N 0.000 description 2
- XBXVXCYESOKNGG-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)C1=C(F)C=CC(S(=O)(=O)NC2CCCCC2)=C1 Chemical compound O=C(NC1=CC=CC=C1)C1=C(F)C=CC(S(=O)(=O)NC2CCCCC2)=C1 XBXVXCYESOKNGG-UHFFFAOYSA-N 0.000 description 2
- ZWOFQKJCYWAXAR-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)C1=CC=CC(S(=O)(=O)CC2CCCCC2)=N1 Chemical compound O=C(NC1=CC=CC=C1)C1=CC=CC(S(=O)(=O)CC2CCCCC2)=N1 ZWOFQKJCYWAXAR-UHFFFAOYSA-N 0.000 description 2
- XZTFFLFDKNXHPA-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)C1=CC=NC(S(=O)(=O)CC2CCCCC2)=C1 Chemical compound O=C(NC1=CC=CC=C1)C1=CC=NC(S(=O)(=O)CC2CCCCC2)=C1 XZTFFLFDKNXHPA-UHFFFAOYSA-N 0.000 description 2
- ZTADQHAUSHNHAQ-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)C1=CN=CC(S(=O)(=O)CC2CCCCC2)=C1 Chemical compound O=C(NC1=CC=CC=C1)C1=CN=CC(S(=O)(=O)CC2CCCCC2)=C1 ZTADQHAUSHNHAQ-UHFFFAOYSA-N 0.000 description 2
- SBFNKFMIDNCYFY-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)C1=CNC(S(=O)(=O)CC2CCCCC2)=N1 Chemical compound O=C(NC1=CC=CC=C1)C1=CNC(S(=O)(=O)CC2CCCCC2)=N1 SBFNKFMIDNCYFY-UHFFFAOYSA-N 0.000 description 2
- NCLAHDXPGPXZSY-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)C1=CSC(S(=O)(=O)CC2CCCCC2)=N1 Chemical compound O=C(NC1=CC=CC=C1)C1=CSC(S(=O)(=O)CC2CCCCC2)=N1 NCLAHDXPGPXZSY-UHFFFAOYSA-N 0.000 description 2
- WATJKTUGHZLEQP-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)C1=NC=CC(S(=O)(=O)CC2CCCCC2)=C1 Chemical compound O=C(NC1=CC=CC=C1)C1=NC=CC(S(=O)(=O)CC2CCCCC2)=C1 WATJKTUGHZLEQP-UHFFFAOYSA-N 0.000 description 2
- FXTBZOYTMDWLLZ-MERQFXBCSA-N S.[C-]#[N+]C1=CC(NC(=O)C2=C(F)C=CC(S(=O)(=O)N[C@H]3CCOC3)=C2F)=CC=C1F Chemical compound S.[C-]#[N+]C1=CC(NC(=O)C2=C(F)C=CC(S(=O)(=O)N[C@H]3CCOC3)=C2F)=CC=C1F FXTBZOYTMDWLLZ-MERQFXBCSA-N 0.000 description 2
- RUWMCNGCKNRYHN-ZYHUDNBSSA-N *.*.CC(C)C[C@@H]1C2=CC=CC=C2O[C@H]1O Chemical compound *.*.CC(C)C[C@@H]1C2=CC=CC=C2O[C@H]1O RUWMCNGCKNRYHN-ZYHUDNBSSA-N 0.000 description 1
- KSMRFNOLMWSLDU-JSGCOSHPSA-N *.*.CC(C)C[C@@H]1CCC2=CC=CC=C2[C@H]1O Chemical compound *.*.CC(C)C[C@@H]1CCC2=CC=CC=C2[C@H]1O KSMRFNOLMWSLDU-JSGCOSHPSA-N 0.000 description 1
- SIZCGHZDNHWBHP-HNAYVOBHSA-N *.*.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCC[C@H]3O)=C2)=C1 Chemical compound *.*.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCC[C@H]3O)=C2)=C1 SIZCGHZDNHWBHP-HNAYVOBHSA-N 0.000 description 1
- RMCDUAPTFCDSGL-IFXJQAMLSA-N *.*.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCO[C@H]3O)=C2)=C1 Chemical compound *.*.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCO[C@H]3O)=C2)=C1 RMCDUAPTFCDSGL-IFXJQAMLSA-N 0.000 description 1
- JJLFGXPMCJTREK-FYYLOGMGSA-N *.*.CC1=CC(NC(=O)C2=CC(S(=O)(=O)C[C@@H]3C4=CC=CC=C4C[C@H]3O)=CC=C2)=CC=C1F Chemical compound *.*.CC1=CC(NC(=O)C2=CC(S(=O)(=O)C[C@@H]3C4=CC=CC=C4C[C@H]3O)=CC=C2)=CC=C1F JJLFGXPMCJTREK-FYYLOGMGSA-N 0.000 description 1
- RWFUIBOPOHFKQA-DHIUTWEWSA-N *.*.CC1=CC(NC(=O)C2=CC(S(=O)(=O)N[C@@H]3CCC4=CC=CC=C4[C@H]3O)=CC=C2)=CC=C1F Chemical compound *.*.CC1=CC(NC(=O)C2=CC(S(=O)(=O)N[C@@H]3CCC4=CC=CC=C4[C@H]3O)=CC=C2)=CC=C1F RWFUIBOPOHFKQA-DHIUTWEWSA-N 0.000 description 1
- ZPFMQHGIBBMKKY-JHEYCYPBSA-N *.CC(C)C[C@H]1C2=CC=CC=C2C[C@H]1O.S Chemical compound *.CC(C)C[C@H]1C2=CC=CC=C2C[C@H]1O.S ZPFMQHGIBBMKKY-JHEYCYPBSA-N 0.000 description 1
- LOLRLAYTXZHYPP-LLVKDONJSA-N *.CC1=C(F)C=CC(NC(=O)C2=CC(S(=O)(=O)N[C@H](C)C(F)(F)F)=CC=C2)=C1 Chemical compound *.CC1=C(F)C=CC(NC(=O)C2=CC(S(=O)(=O)N[C@H](C)C(F)(F)F)=CC=C2)=C1 LOLRLAYTXZHYPP-LLVKDONJSA-N 0.000 description 1
- DVIQZCMPVUAZKD-GIDGLZBFSA-N *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCC[C@@H]3O)=C2)=C1.S Chemical compound *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCC[C@@H]3O)=C2)=C1.S DVIQZCMPVUAZKD-GIDGLZBFSA-N 0.000 description 1
- WGUZQAMZPISGLR-JPJJPTBZSA-N *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCO[C@@H]3O)=C2)=C1.S Chemical compound *.CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCO[C@@H]3O)=C2)=C1.S WGUZQAMZPISGLR-JPJJPTBZSA-N 0.000 description 1
- DZNXMCUZQZHYOH-NSLUPJTDSA-N *.CC1=CC(NC(=O)C2=CC(S(=O)(=O)N[C@H]3C4=CC=CC=C4C[C@H]3O)=CC=C2)=CC=C1F.S Chemical compound *.CC1=CC(NC(=O)C2=CC(S(=O)(=O)N[C@H]3C4=CC=CC=C4C[C@H]3O)=CC=C2)=CC=C1F.S DZNXMCUZQZHYOH-NSLUPJTDSA-N 0.000 description 1
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N C1=CC=C2CCCC2=C1 Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N C1=CC=C2CCCCC2=C1 Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- YPWFNLSXQIGJCK-UHFFFAOYSA-N C1CC2CCC1O2 Chemical compound C1CC2CCC1O2 YPWFNLSXQIGJCK-UHFFFAOYSA-N 0.000 description 1
- QNWHDMQMXLJELA-UHFFFAOYSA-N C1CCOC1.CNS(=O)(=O)C1=C(F)C=CC(C(=O)NC2=CC=C(F)C(C)=C2)=C1.S Chemical compound C1CCOC1.CNS(=O)(=O)C1=C(F)C=CC(C(=O)NC2=CC=C(F)C(C)=C2)=C1.S QNWHDMQMXLJELA-UHFFFAOYSA-N 0.000 description 1
- INFZNMYQZHCMJL-UHFFFAOYSA-N CC(=O)N1CCC(CS(=O)(=O)C2=CC(C(=O)NC3=CC=C(F)C=C3)=CC=C2)CC1 Chemical compound CC(=O)N1CCC(CS(=O)(=O)C2=CC(C(=O)NC3=CC=C(F)C=C3)=CC=C2)CC1 INFZNMYQZHCMJL-UHFFFAOYSA-N 0.000 description 1
- WFJCZADTUPEOSV-UHFFFAOYSA-N CC(=O)N1CCN(S(=O)(=O)C2=CC(C(=O)NC3=CC=C(F)C=C3)=CC=C2)CC1 Chemical compound CC(=O)N1CCN(S(=O)(=O)C2=CC(C(=O)NC3=CC=C(F)C=C3)=CC=C2)CC1 WFJCZADTUPEOSV-UHFFFAOYSA-N 0.000 description 1
- CGZFNDAUJFLLHX-UHFFFAOYSA-N CC(C)(C)BC(=O)NC(C)(C)C Chemical compound CC(C)(C)BC(=O)NC(C)(C)C CGZFNDAUJFLLHX-UHFFFAOYSA-N 0.000 description 1
- DCBDBGZQYXVQRB-UHFFFAOYSA-N CC(C)(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C=C2)=CC=C1 Chemical compound CC(C)(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C=C2)=CC=C1 DCBDBGZQYXVQRB-UHFFFAOYSA-N 0.000 description 1
- AEBCEGWGTIFDCE-UHFFFAOYSA-N CC(C)(C)NS(=O)(=O)C1=C(F)C(C(=O)CC2=CC=C(F)C(C(F)F)=C2)=CC=C1 Chemical compound CC(C)(C)NS(=O)(=O)C1=C(F)C(C(=O)CC2=CC=C(F)C(C(F)F)=C2)=CC=C1 AEBCEGWGTIFDCE-UHFFFAOYSA-N 0.000 description 1
- WFMNLJAQESABBA-UHFFFAOYSA-N CC(C)CC1(C)CC1 Chemical compound CC(C)CC1(C)CC1 WFMNLJAQESABBA-UHFFFAOYSA-N 0.000 description 1
- ZPEFAXBMOZIWER-UHFFFAOYSA-N CC(C)CC1CC(=O)N(C)C1 Chemical compound CC(C)CC1CC(=O)N(C)C1 ZPEFAXBMOZIWER-UHFFFAOYSA-N 0.000 description 1
- DHDJJOUFVGUOSO-UHFFFAOYSA-N CC(C)CC1CCC(=O)N(C)C1 Chemical compound CC(C)CC1CCC(=O)N(C)C1 DHDJJOUFVGUOSO-UHFFFAOYSA-N 0.000 description 1
- PBHVOAGQBZICGP-UHFFFAOYSA-N CC(C)CC1CCN(C)C1=O Chemical compound CC(C)CC1CCN(C)C1=O PBHVOAGQBZICGP-UHFFFAOYSA-N 0.000 description 1
- WKEZLQLUAXFZCZ-UHFFFAOYSA-N CC(C)CC1CN(C(=O)OC(C)(C)C)C1 Chemical compound CC(C)CC1CN(C(=O)OC(C)(C)C)C1 WKEZLQLUAXFZCZ-UHFFFAOYSA-N 0.000 description 1
- NYJQEASBEXVNMA-UHFFFAOYSA-N CC(C)CCCC1CC1 Chemical compound CC(C)CCCC1CC1 NYJQEASBEXVNMA-UHFFFAOYSA-N 0.000 description 1
- RGVKPPOWLYXPGK-UHFFFAOYSA-N CC(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C(F)=C2)=CC=C1 Chemical compound CC(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C(F)=C2)=CC=C1 RGVKPPOWLYXPGK-UHFFFAOYSA-N 0.000 description 1
- RWSOBTZNESTEOZ-UHFFFAOYSA-N CC(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C=C2)=CC=C1 Chemical compound CC(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C=C2)=CC=C1 RWSOBTZNESTEOZ-UHFFFAOYSA-N 0.000 description 1
- OEARSDYKKXGWPO-NJHZPMQHSA-N CC(C)C[C@H]1C2=CC=CC=C2C[C@@H]1O.S.S Chemical compound CC(C)C[C@H]1C2=CC=CC=C2C[C@@H]1O.S.S OEARSDYKKXGWPO-NJHZPMQHSA-N 0.000 description 1
- QRANHLFEJHXVTQ-UHFFFAOYSA-N CC(C)NS(c1cc(C(Nc(cc2)cc(C)c2F)=O)cc(F)c1)(=O)=O Chemical compound CC(C)NS(c1cc(C(Nc(cc2)cc(C)c2F)=O)cc(F)c1)(=O)=O QRANHLFEJHXVTQ-UHFFFAOYSA-N 0.000 description 1
- OAHLQLRLLHSCPU-UHFFFAOYSA-N CC(C)NS(c1cc(C(Nc(cc2)cc(F)c2F)=O)ccc1)(=O)=O Chemical compound CC(C)NS(c1cc(C(Nc(cc2)cc(F)c2F)=O)ccc1)(=O)=O OAHLQLRLLHSCPU-UHFFFAOYSA-N 0.000 description 1
- VTALMLXGKLRQBE-UHFFFAOYSA-N CC(C)NS(c1cc(C(Nc(cc2C)ccc2F)=O)ccc1)(=O)=O Chemical compound CC(C)NS(c1cc(C(Nc(cc2C)ccc2F)=O)ccc1)(=O)=O VTALMLXGKLRQBE-UHFFFAOYSA-N 0.000 description 1
- WHHFRUMSNRZJSF-UHFFFAOYSA-N CC(C)NS(c1cccc(C(Nc2cc(C)cc(C)c2)=O)c1)(=O)=O Chemical compound CC(C)NS(c1cccc(C(Nc2cc(C)cc(C)c2)=O)c1)(=O)=O WHHFRUMSNRZJSF-UHFFFAOYSA-N 0.000 description 1
- QEQRWUSGBTZOEB-UHFFFAOYSA-N CC(CCc1ccccc1)NS(c1cc(C(Nc(cc2C)ccc2F)=O)ccc1)(=O)=O Chemical compound CC(CCc1ccccc1)NS(c1cc(C(Nc(cc2C)ccc2F)=O)ccc1)(=O)=O QEQRWUSGBTZOEB-UHFFFAOYSA-N 0.000 description 1
- AMKZQECLTZVINS-UHFFFAOYSA-N CC1(COC1)NS(c(cc1)cc(C(Nc(cc2)cc(C(F)(F)F)c2F)=O)c1Cl)(=O)=O Chemical compound CC1(COC1)NS(c(cc1)cc(C(Nc(cc2)cc(C(F)(F)F)c2F)=O)c1Cl)(=O)=O AMKZQECLTZVINS-UHFFFAOYSA-N 0.000 description 1
- JHMGQYLHWHOCSZ-UHFFFAOYSA-N CC1(COC1)NS(c1cc(C(Nc(cc2)cc(C(F)(F)F)c2F)=O)c(C)cc1)(=O)=O Chemical compound CC1(COC1)NS(c1cc(C(Nc(cc2)cc(C(F)(F)F)c2F)=O)c(C)cc1)(=O)=O JHMGQYLHWHOCSZ-UHFFFAOYSA-N 0.000 description 1
- SCHPPMHEPQWAFO-UHFFFAOYSA-N CC1(COC1)NS(c1cccc(C(Nc(cc2C(F)F)ccc2F)=O)c1F)(=O)=O Chemical compound CC1(COC1)NS(c1cccc(C(Nc(cc2C(F)F)ccc2F)=O)c1F)(=O)=O SCHPPMHEPQWAFO-UHFFFAOYSA-N 0.000 description 1
- AWFRKAGGRFIWMU-UHFFFAOYSA-N CC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC(O)=C(F)C=C3)=CC=C2)CCC1 Chemical compound CC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC(O)=C(F)C=C3)=CC=C2)CCC1 AWFRKAGGRFIWMU-UHFFFAOYSA-N 0.000 description 1
- QUTMTRUMODYGAM-UHFFFAOYSA-N CC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC(O)=C(F)C=C3)=CC=C2)COC1 Chemical compound CC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC(O)=C(F)C=C3)=CC=C2)COC1 QUTMTRUMODYGAM-UHFFFAOYSA-N 0.000 description 1
- GUKYTSNYLBJTTA-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC(S(=O)(=O)N3CCCCC3)=CC=C2)=C1.CC1=C(F)C=CC(NC(=O)C2=CC(S(=O)(=O)N3CCCCC3)=CC=C2F)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC(S(=O)(=O)N3CCCCC3)=CC=C2)=C1.CC1=C(F)C=CC(NC(=O)C2=CC(S(=O)(=O)N3CCCCC3)=CC=C2F)=C1 GUKYTSNYLBJTTA-UHFFFAOYSA-N 0.000 description 1
- BLVULSYZVBZOLS-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)CC3=NC=CC=C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)CC3=NC=CC=C3)=C2)=C1 BLVULSYZVBZOLS-UHFFFAOYSA-N 0.000 description 1
- AVOOTSDQJFYLIG-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)CC3CCCCN3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)CC3CCCCN3)=C2)=C1 AVOOTSDQJFYLIG-UHFFFAOYSA-N 0.000 description 1
- DDCCNFVVXSXUCM-UHFFFAOYSA-N CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3(C)CN(C(=O)OC(C)(C)C)C3)=C2)=C1 Chemical compound CC1=C(F)C=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC3(C)CN(C(=O)OC(C)(C)C)C3)=C2)=C1 DDCCNFVVXSXUCM-UHFFFAOYSA-N 0.000 description 1
- UDVGYUFFWZVHCN-UHFFFAOYSA-N CC1=C(NC(=O)C2=CC(S(=O)(=O)NC3CCCCC3)=CC=C2)C=CC=C1 Chemical compound CC1=C(NC(=O)C2=CC(S(=O)(=O)NC3CCCCC3)=CC=C2)C=CC=C1 UDVGYUFFWZVHCN-UHFFFAOYSA-N 0.000 description 1
- CZUHJOJREUVEBC-UHFFFAOYSA-N CC1=C(S(=O)(=O)N2CCCCC2)C(C)=C(C(=O)NC2=CC=CC=C2)N1 Chemical compound CC1=C(S(=O)(=O)N2CCCCC2)C(C)=C(C(=O)NC2=CC=CC=C2)N1 CZUHJOJREUVEBC-UHFFFAOYSA-N 0.000 description 1
- FQQFLHLQEFIBGG-UHFFFAOYSA-N CC1=CC(C)=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C)=C2)=C1 Chemical compound CC1=CC(C)=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C)=C2)=C1 FQQFLHLQEFIBGG-UHFFFAOYSA-N 0.000 description 1
- WUABERUCYBQHOH-UHFFFAOYSA-N CC1=CC(NC(=O)C2=C(F)C(S(=O)(=O)NC3(C)CCC3)=CC(Br)=C2C)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=C(F)C(S(=O)(=O)NC3(C)CCC3)=CC(Br)=C2C)=CC=C1F WUABERUCYBQHOH-UHFFFAOYSA-N 0.000 description 1
- OPZJANDLHUZZPS-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3CC(=O)N(C)C3)=CC=C2)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3CC(=O)N(C)C3)=CC=C2)=CC=C1F OPZJANDLHUZZPS-UHFFFAOYSA-N 0.000 description 1
- FKOSQCLMMXUJAF-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3CCC(=O)N(C)C3)=CC=C2)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3CCC(=O)N(C)C3)=CC=C2)=CC=C1F FKOSQCLMMXUJAF-UHFFFAOYSA-N 0.000 description 1
- FLKDQVGBNUKMDT-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3CCN(C)C3=O)=CC=C2)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3CCN(C)C3=O)=CC=C2)=CC=C1F FLKDQVGBNUKMDT-UHFFFAOYSA-N 0.000 description 1
- MLKDPQKHUMDOGD-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3CN(C(=O)OC(C)(C)C)C3)=CC=C2)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3CN(C(=O)OC(C)(C)C)C3)=CC=C2)=CC=C1F MLKDPQKHUMDOGD-UHFFFAOYSA-N 0.000 description 1
- PWHGZRKVVYEQLU-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3COCC3O)=CC=C2)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)CC3COCC3O)=CC=C2)=CC=C1F PWHGZRKVVYEQLU-UHFFFAOYSA-N 0.000 description 1
- XUSOYURSMCWVNY-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)CCCC3CC3)=CC=C2)=CC=C1F Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)CCCC3CC3)=CC=C2)=CC=C1F XUSOYURSMCWVNY-UHFFFAOYSA-N 0.000 description 1
- BMPRWTKKCKESQJ-CPTHQKRGSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)C[C@H]3C4=CC=CC=C4C[C@@H]3O)=CC=C2)=CC=C1F.S.S Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)C[C@H]3C4=CC=CC=C4C[C@@H]3O)=CC=C2)=CC=C1F.S.S BMPRWTKKCKESQJ-CPTHQKRGSA-N 0.000 description 1
- GQHWURAMDLJQMG-UQKRIMTDSA-N CC1=CC(NC(=O)C2=CC(S(=O)(=O)N[C@H]3CCOC3)=C(F)C=C2)=CC=C1F.S Chemical compound CC1=CC(NC(=O)C2=CC(S(=O)(=O)N[C@H]3CCOC3)=C(F)C=C2)=CC=C1F.S GQHWURAMDLJQMG-UQKRIMTDSA-N 0.000 description 1
- UZXQYBRUDZTUPA-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C)=C2)=CC(C)=C1F Chemical compound CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)CC(C)C)=C2)=CC(C)=C1F UZXQYBRUDZTUPA-UHFFFAOYSA-N 0.000 description 1
- WQPJSWNGHANQHI-BTQNPOSSSA-N CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCOC3)=C2F)=CC=C1F.S Chemical compound CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@@H]3CCOC3)=C2F)=CC=C1F.S WQPJSWNGHANQHI-BTQNPOSSSA-N 0.000 description 1
- WQPJSWNGHANQHI-ZOWNYOTGSA-N CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2F)=CC=C1F.S Chemical compound CC1=CC(NC(=O)C2=CC=CC(S(=O)(=O)C[C@H]3CCOC3)=C2F)=CC=C1F.S WQPJSWNGHANQHI-ZOWNYOTGSA-N 0.000 description 1
- ZZFKVWQTJKQCNT-UHFFFAOYSA-N CC1=CC=CC(NC(=O)C2=CC(S(=O)(=O)N3CCCCC3)=CC=C2Cl)=C1 Chemical compound CC1=CC=CC(NC(=O)C2=CC(S(=O)(=O)N3CCCCC3)=CC=C2Cl)=C1 ZZFKVWQTJKQCNT-UHFFFAOYSA-N 0.000 description 1
- TVEKAMAVYVEAPA-UHFFFAOYSA-N CC1=CC=CC(NC(=O)C2=CC(S(=O)(=O)N3CCOCC3)=CC=C2Cl)=C1 Chemical compound CC1=CC=CC(NC(=O)C2=CC(S(=O)(=O)N3CCOCC3)=CC=C2Cl)=C1 TVEKAMAVYVEAPA-UHFFFAOYSA-N 0.000 description 1
- DIUGYPAVPJILFZ-UHFFFAOYSA-N CC1CC2=CC=CC=C2C1C Chemical compound CC1CC2=CC=CC=C2C1C DIUGYPAVPJILFZ-UHFFFAOYSA-N 0.000 description 1
- OPGLMLZGLGTLFY-UHFFFAOYSA-N CCC(C)(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C(C)=C2)=CC=C1 Chemical compound CCC(C)(C)CS(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C(C)=C2)=CC=C1 OPGLMLZGLGTLFY-UHFFFAOYSA-N 0.000 description 1
- YCISIZIUZJEJLM-UHFFFAOYSA-N CCC(C)(C)NS(=O)(=O)C1=CC=CC(C(=O)NC2=CC(C)=C(F)C=C2)=C1 Chemical compound CCC(C)(C)NS(=O)(=O)C1=CC=CC(C(=O)NC2=CC(C)=C(F)C=C2)=C1 YCISIZIUZJEJLM-UHFFFAOYSA-N 0.000 description 1
- QHRLHOIVNVHVQX-UHFFFAOYSA-N CCC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC=C(F)C=C3)=CC=C2)CC1 Chemical compound CCC1(CS(=O)(=O)C2=CC(C(=O)NC3=CC=C(F)C=C3)=CC=C2)CC1 QHRLHOIVNVHVQX-UHFFFAOYSA-N 0.000 description 1
- LPJWBTWVRDOWJX-UHFFFAOYSA-N CCC1(CS(=O)(=O)C2=CC=CC(C(=O)CC3=CC(C)=C(F)C=C3)=C2)CC1 Chemical compound CCC1(CS(=O)(=O)C2=CC=CC(C(=O)CC3=CC(C)=C(F)C=C3)=C2)CC1 LPJWBTWVRDOWJX-UHFFFAOYSA-N 0.000 description 1
- LIPVFYKMXSPWGG-UHFFFAOYSA-N CCC1(NS(=O)(=O)C2=CC=CC(C(=O)NC3=CC(C)=C(F)C=C3)=C2)CC1 Chemical compound CCC1(NS(=O)(=O)C2=CC=CC(C(=O)NC3=CC(C)=C(F)C=C3)=C2)CC1 LIPVFYKMXSPWGG-UHFFFAOYSA-N 0.000 description 1
- FJUSLKCMGONACE-UHFFFAOYSA-N CCC1(NS(=O)(=O)C2=CC=CC(C(=O)NC3=CC=C(F)C=C3)=C2)CC1 Chemical compound CCC1(NS(=O)(=O)C2=CC=CC(C(=O)NC3=CC=C(F)C=C3)=C2)CC1 FJUSLKCMGONACE-UHFFFAOYSA-N 0.000 description 1
- JEZKXNVTNUFOOH-UHFFFAOYSA-N CCN(CC)S(=O)(=O)C1=CC=C(Cl)C(C(=O)CC2=CC=CC=C2)=C1 Chemical compound CCN(CC)S(=O)(=O)C1=CC=C(Cl)C(C(=O)CC2=CC=CC=C2)=C1 JEZKXNVTNUFOOH-UHFFFAOYSA-N 0.000 description 1
- HRCBDSIADXEVHF-UHFFFAOYSA-N CN(C(C1CCCCC1)=O)S(c1cc(C(Nc(cc2)ccc2F)=O)ccc1)(=O)=O Chemical compound CN(C(C1CCCCC1)=O)S(c1cc(C(Nc(cc2)ccc2F)=O)ccc1)(=O)=O HRCBDSIADXEVHF-UHFFFAOYSA-N 0.000 description 1
- FKFWCNPTPFRUAH-UHFFFAOYSA-N CN(C)S(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C=C2)=CC=C1 Chemical compound CN(C)S(=O)(=O)C1=CC(C(=O)NC2=CC=C(F)C=C2)=CC=C1 FKFWCNPTPFRUAH-UHFFFAOYSA-N 0.000 description 1
- ZCKWHFCBPXGRGM-UHFFFAOYSA-N CN1CC2(CCOC2)C1 Chemical compound CN1CC2(CCOC2)C1 ZCKWHFCBPXGRGM-UHFFFAOYSA-N 0.000 description 1
- XAOIBIMSYMZQMW-UHFFFAOYSA-N CN1CC2(COC2)C1 Chemical compound CN1CC2(COC2)C1 XAOIBIMSYMZQMW-UHFFFAOYSA-N 0.000 description 1
- CJTGKHFUXLFDCP-UHFFFAOYSA-N CN1CCC(CS(=O)(=O)C2=CC(C(=O)NC3=CC=C(F)C=C3)=CC=C2)CC1 Chemical compound CN1CCC(CS(=O)(=O)C2=CC(C(=O)NC3=CC=C(F)C=C3)=CC=C2)CC1 CJTGKHFUXLFDCP-UHFFFAOYSA-N 0.000 description 1
- WFJLSQTVUBNDPN-UHFFFAOYSA-N CN1CCC12COC2 Chemical compound CN1CCC12COC2 WFJLSQTVUBNDPN-UHFFFAOYSA-N 0.000 description 1
- YLPBUMOJYDPQJB-UHFFFAOYSA-N CN1CCC2(CC1)OCCO2 Chemical compound CN1CCC2(CC1)OCCO2 YLPBUMOJYDPQJB-UHFFFAOYSA-N 0.000 description 1
- YIBBUYIPJSIXAU-UHFFFAOYSA-N COC1=CC=C(NC(=O)C2=CC(S(=O)(=O)N3CCCCCC3)=C(Cl)C=C2)C=C1 Chemical compound COC1=CC=C(NC(=O)C2=CC(S(=O)(=O)N3CCCCCC3)=C(Cl)C=C2)C=C1 YIBBUYIPJSIXAU-UHFFFAOYSA-N 0.000 description 1
- YSDMFHFQDNDJFE-UHFFFAOYSA-N COc(cc(cc1)NC(c2cc(S3(=O)=[O]C4(COC4)N3)ccc2)=O)c1F Chemical compound COc(cc(cc1)NC(c2cc(S3(=O)=[O]C4(COC4)N3)ccc2)=O)c1F YSDMFHFQDNDJFE-UHFFFAOYSA-N 0.000 description 1
- UTTWGRIVSYYTGX-INIZCTEOSA-N C[C@@H](C1CCCCC1)NS(c1cccc(C(Nc(cc2)cc(C)c2F)=O)c1)(=O)=O Chemical compound C[C@@H](C1CCCCC1)NS(c1cccc(C(Nc(cc2)cc(C)c2F)=O)c1)(=O)=O UTTWGRIVSYYTGX-INIZCTEOSA-N 0.000 description 1
- PKQSDBLBXARPED-MRXNPFEDSA-N C[C@H](c1ccccc1)NS(c1cc(C(Nc(cc2C)ccc2F)=O)ccc1)(=O)=O Chemical compound C[C@H](c1ccccc1)NS(c1cc(C(Nc(cc2C)ccc2F)=O)ccc1)(=O)=O PKQSDBLBXARPED-MRXNPFEDSA-N 0.000 description 1
- LKAYZPMXQXWSGB-ZDUSSCGKSA-N Cc(c(F)c(cc1)NC(c2cc(S(N[C@@H]3COCC3)(=O)=O)ccc2)=O)c1F Chemical compound Cc(c(F)c(cc1)NC(c2cc(S(N[C@@H]3COCC3)(=O)=O)ccc2)=O)c1F LKAYZPMXQXWSGB-ZDUSSCGKSA-N 0.000 description 1
- QSCQNVNHESAVFB-LBPRGKRZSA-N Cc1cc(NC(c(c(Cl)ccc2S(N[C@@H]3COCC3)(=O)=O)c2Cl)=O)ccc1F Chemical compound Cc1cc(NC(c(c(Cl)ccc2S(N[C@@H]3COCC3)(=O)=O)c2Cl)=O)ccc1F QSCQNVNHESAVFB-LBPRGKRZSA-N 0.000 description 1
- JIZGLOVJKCSHTH-HNNXBMFYSA-N Cc1cc(NC(c2cccc(S(N[C@@H]3COCC3)(=O)=O)c2)=O)ccc1F Chemical compound Cc1cc(NC(c2cccc(S(N[C@@H]3COCC3)(=O)=O)c2)=O)ccc1F JIZGLOVJKCSHTH-HNNXBMFYSA-N 0.000 description 1
- JJWLHSUNEQMQPH-FCHUYYIVSA-N Cc1cc(NC(c2cccc(S(N[C@@H]3c4ccccc4C[C@@H]3O)(=O)=O)c2)=O)ccc1F Chemical compound Cc1cc(NC(c2cccc(S(N[C@@H]3c4ccccc4C[C@@H]3O)(=O)=O)c2)=O)ccc1F JJWLHSUNEQMQPH-FCHUYYIVSA-N 0.000 description 1
- STYLYGRZHRZIHU-LBPRGKRZSA-N N#Cc1cc(NC(c(c(F)ccc2S(N[C@@H]3COCC3)(=O)=O)c2F)=O)ccc1F Chemical compound N#Cc1cc(NC(c(c(F)ccc2S(N[C@@H]3COCC3)(=O)=O)c2F)=O)ccc1F STYLYGRZHRZIHU-LBPRGKRZSA-N 0.000 description 1
- SYEZAOYGQLTHLJ-UHFFFAOYSA-N N#Cc1cc(NC(c2cccc(S(NC3CCCC3)(=O)=O)c2)=O)ccc1 Chemical compound N#Cc1cc(NC(c2cccc(S(NC3CCCC3)(=O)=O)c2)=O)ccc1 SYEZAOYGQLTHLJ-UHFFFAOYSA-N 0.000 description 1
- VUMWZLWQJSYMES-UHFFFAOYSA-N O=C(CC1=CC=C(Br)C=C1)C1=CC=C(Cl)C(S(=O)(=O)N2CCCCCC2)=C1 Chemical compound O=C(CC1=CC=C(Br)C=C1)C1=CC=C(Cl)C(S(=O)(=O)N2CCCCCC2)=C1 VUMWZLWQJSYMES-UHFFFAOYSA-N 0.000 description 1
- NIFKBPMYPDZILY-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)C1=CC(S(=O)(=O)C2CCCCC2)=CC=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)C1=CC(S(=O)(=O)C2CCCCC2)=CC=C1 NIFKBPMYPDZILY-UHFFFAOYSA-N 0.000 description 1
- FAEYHKQSQMOWOS-UHFFFAOYSA-N O=C(CC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)N2CCOCC2)=C1 Chemical compound O=C(CC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)N2CCOCC2)=C1 FAEYHKQSQMOWOS-UHFFFAOYSA-N 0.000 description 1
- MQLBWZGUSRMECL-UHFFFAOYSA-N O=C(CC1=CC=CC=C1)C1=CC=C(F)C(S(=O)(=O)NC2CCCCC2)=C1 Chemical compound O=C(CC1=CC=CC=C1)C1=CC=C(F)C(S(=O)(=O)NC2CCCCC2)=C1 MQLBWZGUSRMECL-UHFFFAOYSA-N 0.000 description 1
- YDPGUSJTBPYZQG-UHFFFAOYSA-N O=C(CC1=CC=CC=C1Cl)C1=CC=C(Cl)C(S(=O)(=O)N2CCCCCC2)=C1 Chemical compound O=C(CC1=CC=CC=C1Cl)C1=CC=C(Cl)C(S(=O)(=O)N2CCCCCC2)=C1 YDPGUSJTBPYZQG-UHFFFAOYSA-N 0.000 description 1
- ZJQXQMXFUNQKEU-UHFFFAOYSA-N O=C(NC1=C(Cl)C=CC=C1)C1=C(F)C=CC(S(=O)(=O)NC2CCCCC2)=C1 Chemical compound O=C(NC1=C(Cl)C=CC=C1)C1=C(F)C=CC(S(=O)(=O)NC2CCCCC2)=C1 ZJQXQMXFUNQKEU-UHFFFAOYSA-N 0.000 description 1
- QDGIAAFRLAWABZ-UHFFFAOYSA-N O=C(NC1=CC=C(C(F)(F)F)C=C1)C1=C(F)C=CC(S(=O)(=O)CC2CCCC2)=C1 Chemical compound O=C(NC1=CC=C(C(F)(F)F)C=C1)C1=C(F)C=CC(S(=O)(=O)CC2CCCC2)=C1 QDGIAAFRLAWABZ-UHFFFAOYSA-N 0.000 description 1
- QYJCBUVIXBEVRY-UHFFFAOYSA-N O=C(NC1=CC=C(Cl)C=C1)C1=C(F)C=CC(S(=O)(=O)CC2CCCC2)=C1 Chemical compound O=C(NC1=CC=C(Cl)C=C1)C1=C(F)C=CC(S(=O)(=O)CC2CCCC2)=C1 QYJCBUVIXBEVRY-UHFFFAOYSA-N 0.000 description 1
- SVWFYLMWBRUPCF-UHFFFAOYSA-N O=C(NC1=CC=C(Cl)C=C1)C1=C(F)C=CC(S(=O)(=O)NC2CCCCC2)=C1 Chemical compound O=C(NC1=CC=C(Cl)C=C1)C1=C(F)C=CC(S(=O)(=O)NC2CCCCC2)=C1 SVWFYLMWBRUPCF-UHFFFAOYSA-N 0.000 description 1
- YHFOMSGCUIBJCV-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1=C(Cl)C=CC(S(=O)(=O)N2CCCCC2)=C1 Chemical compound O=C(NC1=CC=C(F)C=C1)C1=C(Cl)C=CC(S(=O)(=O)N2CCCCC2)=C1 YHFOMSGCUIBJCV-UHFFFAOYSA-N 0.000 description 1
- YEOFULUGQCHPGL-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1=C(F)C=CC(S(=O)(=O)CC2CCCC2)=C1 Chemical compound O=C(NC1=CC=C(F)C=C1)C1=C(F)C=CC(S(=O)(=O)CC2CCCC2)=C1 YEOFULUGQCHPGL-UHFFFAOYSA-N 0.000 description 1
- JZWSLTYEEKUMDO-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1=C(F)C=CC(S(=O)(=O)N2CCC3(CC2)OCCO3)=C1 Chemical compound O=C(NC1=CC=C(F)C=C1)C1=C(F)C=CC(S(=O)(=O)N2CCC3(CC2)OCCO3)=C1 JZWSLTYEEKUMDO-UHFFFAOYSA-N 0.000 description 1
- PSRMIHLDUJDOIQ-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1=CC(S(=O)(=O)CC2CCCC2)=C(Cl)C=C1Cl Chemical compound O=C(NC1=CC=C(F)C=C1)C1=CC(S(=O)(=O)CC2CCCC2)=C(Cl)C=C1Cl PSRMIHLDUJDOIQ-UHFFFAOYSA-N 0.000 description 1
- DWJCXYCEHCFLOW-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1=CC(S(=O)(=O)N2CCCCC2)=CS1 Chemical compound O=C(NC1=CC=C(F)C=C1)C1=CC(S(=O)(=O)N2CCCCC2)=CS1 DWJCXYCEHCFLOW-UHFFFAOYSA-N 0.000 description 1
- XAXNWADSDHAIPN-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1=CC(S(=O)(=O)N2CCOCC2)=CC=C1Cl Chemical compound O=C(NC1=CC=C(F)C=C1)C1=CC(S(=O)(=O)N2CCOCC2)=CC=C1Cl XAXNWADSDHAIPN-UHFFFAOYSA-N 0.000 description 1
- RLOZBVNPDZOOFU-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1=CC=C(Cl)C(S(=O)(=O)N2CCCCCC2)=C1 Chemical compound O=C(NC1=CC=C(F)C=C1)C1=CC=C(Cl)C(S(=O)(=O)N2CCCCCC2)=C1 RLOZBVNPDZOOFU-UHFFFAOYSA-N 0.000 description 1
- YIKOBJIPEQAQJV-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1=CC=C(S(=O)(=O)N2CCCCC2)O1 Chemical compound O=C(NC1=CC=C(F)C=C1)C1=CC=C(S(=O)(=O)N2CCCCC2)O1 YIKOBJIPEQAQJV-UHFFFAOYSA-N 0.000 description 1
- UFJAKNFXMDLHKM-UHFFFAOYSA-N O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)N2CCCC2)=C1 Chemical compound O=C(NC1=CC=C(F)C=C1)C1=CC=CC(S(=O)(=O)N2CCCC2)=C1 UFJAKNFXMDLHKM-UHFFFAOYSA-N 0.000 description 1
- RZCNGMBUAUZLDU-UHFFFAOYSA-N O=C(NC1=CC=CC(F)=C1)C1=CC(S(=O)(=O)N2CCCC2)=C(Cl)C=C1Cl Chemical compound O=C(NC1=CC=CC(F)=C1)C1=CC(S(=O)(=O)N2CCCC2)=C(Cl)C=C1Cl RZCNGMBUAUZLDU-UHFFFAOYSA-N 0.000 description 1
- KENJNQGKULJCIX-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)C1=CC(S(=O)(=O)N2CCCCC2)=C(Cl)C=C1Cl Chemical compound O=C(NC1=CC=CC=C1)C1=CC(S(=O)(=O)N2CCCCC2)=C(Cl)C=C1Cl KENJNQGKULJCIX-UHFFFAOYSA-N 0.000 description 1
- XELSNGAOMRJNEG-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)C1=CC(S(=O)(=O)N2CCCCC2)=CS1 Chemical compound O=C(NC1=CC=CC=C1)C1=CC(S(=O)(=O)N2CCCCC2)=CS1 XELSNGAOMRJNEG-UHFFFAOYSA-N 0.000 description 1
- SRLSPDHRPIVEBK-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)C1=CC(S(=O)(=O)NC2CCCCC2)=CS1 Chemical compound O=C(NC1=CC=CC=C1)C1=CC(S(=O)(=O)NC2CCCCC2)=CS1 SRLSPDHRPIVEBK-UHFFFAOYSA-N 0.000 description 1
- XOYCHWHQJKTPKY-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)C1=CC(S(=O)(=O)NCC2=CC=CC=C2)=CC=C1Cl Chemical compound O=C(NC1=CC=CC=C1)C1=CC(S(=O)(=O)NCC2=CC=CC=C2)=CC=C1Cl XOYCHWHQJKTPKY-UHFFFAOYSA-N 0.000 description 1
- YPQZPYKRQJRRKB-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)C1=CC=C(S(=O)(=O)N2CCCCC2)O1 Chemical compound O=C(NC1=CC=CC=C1)C1=CC=C(S(=O)(=O)N2CCCCC2)O1 YPQZPYKRQJRRKB-UHFFFAOYSA-N 0.000 description 1
- FHZBSSREDIYRQE-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)C1=CC=CC(S(=O)(=O)CC2CC2)=C1 Chemical compound O=C(NC1=CC=CC=C1)C1=CC=CC(S(=O)(=O)CC2CC2)=C1 FHZBSSREDIYRQE-UHFFFAOYSA-N 0.000 description 1
- RVSNKQKUCGVTBJ-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)C1=CC=CC(S(=O)(=O)CC2CCCC2)=C1 Chemical compound O=C(NC1=CC=CC=C1)C1=CC=CC(S(=O)(=O)CC2CCCC2)=C1 RVSNKQKUCGVTBJ-UHFFFAOYSA-N 0.000 description 1
- LHMVLJUNQIYXJU-JTQLQIEISA-N O=C(c(c(F)ccc1S(N[C@@H]2COCC2)(=O)=O)c1F)Nc(cc1Cl)ccc1F Chemical compound O=C(c(c(F)ccc1S(N[C@@H]2COCC2)(=O)=O)c1F)Nc(cc1Cl)ccc1F LHMVLJUNQIYXJU-JTQLQIEISA-N 0.000 description 1
- VFZATMSWZCHOMY-UHFFFAOYSA-N O=C(c1cc(S(NC2CCCCC2)(=O)=O)ccn1)Nc1ccccc1 Chemical compound O=C(c1cc(S(NC2CCCCC2)(=O)=O)ccn1)Nc1ccccc1 VFZATMSWZCHOMY-UHFFFAOYSA-N 0.000 description 1
- MEOOYFGDROLQQB-UHFFFAOYSA-N O=C(c1cc(S(NC2CCCCC2)(=O)=O)cnc1)Nc1ccccc1 Chemical compound O=C(c1cc(S(NC2CCCCC2)(=O)=O)cnc1)Nc1ccccc1 MEOOYFGDROLQQB-UHFFFAOYSA-N 0.000 description 1
- LEQLPLARJSEMAM-UHFFFAOYSA-N O=C(c1cccc(S(N(CCCC2)C2=O)(=O)=O)c1)Nc(cc1)ccc1F Chemical compound O=C(c1cccc(S(N(CCCC2)C2=O)(=O)=O)c1)Nc(cc1)ccc1F LEQLPLARJSEMAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/14—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/46—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
- C07D333/48—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Definitions
- the Hepatitis B virus is an enveloped, partially double-stranded DNA (dsDNA) virus of the Hepadnavirus family (Hepadnaviridae). Its genome contains 4 overlapping reading frames: the precore/core gene; the polymerase gene; the L, M, and S genes, which encode for the 3 envelope proteins; and the X gene.
- the partially double-stranded DNA genome (the relaxed circular DNA; rcDNA) is converted to a covalently closed circular DNA (cccDNA) in the nucleus of the host cell and the viral mRNAs are transcribed.
- the pregenomic RNA (pgRNA), which also codes for core protein and Pol, serves as the template for reverse transcription, which regenerates the partially dsDNA genome (rcDNA) in the nucleocapsid.
- HBV has caused epidemics in parts of Asia and Africa, and it is endemic in China. HBV has infected approximately 2 billion people worldwide of which approximately 350 million people have developed chronic infections. The virus causes the disease hepatitis B and chronic infection is correlated with a strongly increased risk for the development cirrhosis and hepatocellular carcinoma.
- Transmission of hepatitis B virus results from exposure to infectious blood or body fluids, while viral DNA has been detected in the saliva, tears, and urine of chronic carriers with high titer DNA in serum.
- heteroaryldihydropyrimidines were identified as a class of HBV inhibitors in tissue culture and animal models (Weber et al., Antiviral Res. 54: 69-78).
- WO2013/006394 published on Jan. 10, 2013, and WO2013/096744, published on Jun. 27, 2013 relate to subclasses of Sulphamoyl-arylamides active against HBV.
- HBV direct antivirals may encounter are toxicity, mutagenicity, lack of selectivity, poor efficacy, poor bioavailability and difficulty of synthesis.
- HBV inhibitors that may overcome at least one of these disadvantages or that have additional advantages such as increased potency or an increased safety window.
- the present invention relates to compounds of Formula (I)
- the invention further relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound of Formula (I), and a pharmaceutically acceptable carrier.
- the invention also relates to the compounds of Formula (I) for use as a medicament, preferably for use in the prevention or treatment of an HBV infection in a mammal.
- the invention relates to a combination of a compound of Formula (I), and another HBV inhibitor.
- C 1-3 alkyl refers to a hydrocarbyl radical of Formula C n H 2n+1 wherein n is a number ranging from 1 to 3. In case C 1-3 alkyl is coupled to a further radical, it refers to a Formula C n H 2n .
- C 1-3 alkyl groups comprise from 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms.
- C 1-3 alkyl includes all linear, or branched alkyl groups with between 1 and 3 carbon atoms, and thus includes such as for example methyl, ethyl, n-propyl, and i-propyl.
- C 1-4 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as the group defined for C 1-3 alkyl and butyl and the like.
- C 1-6 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the groups defined for
- C 1-4 alkenyl as a group or part of a group defines straight or branched chain hydrocarbon radicals having from 1 to 4 carbon atoms with at least one double bond at any possible position.
- alkenyls are ethenyl, propenyl, 1-butenyl, 2-butenyl.
- C 1-6 alkenyl as a group or part of a group defines straight or branched chain hydrocarbon radicals having from 1 to 6 carbon atoms with at least one double bond.
- C 1-3 alkyloxy refers to a radical having the Formula —OR c wherein R c is C 1-3 alkyl.
- suitable C 1-3 alkyloxy include methyloxy (also methoxy), ethyloxy (also ethoxy), propyloxy and isopropyloxy.
- oxo, C( ⁇ O), or carbonyl refers to a group composed of a carbon atom double bonded to an oxygen atom.
- 3-7 membered saturated ring means saturated cyclic hydrocarbon with 3, 4, 5, 6 or 7 carbon atoms and is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
- Such saturated ring optionally contains one or more heteroatoms, such that at least one carbon atom is replaced by a heteroatom selected from N, O and S, in particular from N and O.
- heteroatoms such that at least one carbon atom is replaced by a heteroatom selected from N, O and S, in particular from N and O.
- Examples include oxetane, azetidine, tetrahydro-2H-pyranyl, piperidinyl, tetrahydrofuranyl, morpholinyl and pyrrolidinyl.
- Preferred are saturated cyclic hydrocarbon with 3 or 4 carbon atoms and 1 oxygen atom. Examples include oxetane and tetrahydrofuranyl.
- aryl monocyclic 5 to 6 membered aromatic ring
- a preferred example of an aryl group is phenyl.
- Such saturated ring optionally contains one or more heteroatoms each independently selected from the group consisting of O, S and N (“heteroaryl”)
- a heteroaryl group need only have some degree of aromatic character.
- Illustrative examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrimidyl, pyrazyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3,)- and (1,2,4)-triazolyl, pyrazinyl, pyrimidinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, isoxazolyl, and oxazolyl.
- a heteroaryl group can be unsubstituted or substituted with one or more suitable substituents.
- 6-10 membered bicyclic ring indicates a saturated bi-cyclic ring with 6-7-8-9 or 10 atoms.
- Such saturated bi-cyclic ring optionally contains one or more heteroatoms, such that at least one carbon atom is replaced by a heteroatom selected from N, O and S, in particular from N and O.
- 6-10 membered bicyclic ring as used herein arean 1,4-dioxa-8-azaspiro[4.5]decyl moiety indicating a group with structural formula
- 6-10 membered bridged ring indicates a saturated bridged ring with 6-7-8-9 or 10 atoms.
- saturated bi-cyclic ring optionally contains one or more heteroatoms, such that at least one carbon atom is replaced by a heteroatom selected from N, O and S, in particular from N and O.
- An example of such 6-10 membered bridged ring as used herein is -oxabicyclo[2.2.1]heptan represented by structure
- a dihydroindenyl moiety represents a group with structural formula
- Such dihydroindenyl moiety can be optionally substituted with OH.
- a 2-hydroxy-2,3-dihydro-1H-indenyl moiety indicates a group with structural formula
- a tetrahydronaphtalenyl moiety represents a group with structural formula
- the attachment to the main structure may be anywhere on such moiety as long as it is chemically stable.
- pyrrolyl may be 1H-pyrrolyl or 2H-pyrrolyl.
- halo and halogen are generic to fluoro, chloro, bromo or iodo. Preferred halogens are fluoro and Chloro.
- radical positions on any molecular moiety used in the definitions may be anywhere on such moiety as long as it is chemically stable.
- pyridyl includes 2-pyridyl, 3-pyridyl and 4-pyridyl
- pentyl includes 1-pentyl, 2-pentyl and 3-pentyl.
- Positions indicated on phenyl are indicated relative to the bond connecting the phenyl to the main structure.
- An example with regard to the position of R 4 any location is indicated relative to the nitrogen (*) connected to the main structure:
- the salts of the compounds of formula (I) are those wherein the counter ion is pharmaceutically or physiologically acceptable.
- salts having a pharmaceutically unacceptable counter ion may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound of formula (I). All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
- the pharmaceutically acceptable or physiologically tolerable addition salt forms which the compounds of the present invention are able to form can conveniently be prepared using the appropriate acids, such as, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; hemisulphuric, nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, aspartic, dodecylsulphuric, heptanoic, hexanoic, nicotinic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
- salts also comprises the hydrates and the solvent addition forms that the compounds of the present invention are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.
- present compounds may also exist in their tautomeric forms for example, tautomeric forms of amide (—C( ⁇ O)—NH—) groups are iminoalcohols (—C(OH) ⁇ N—). Tautomeric forms, although not explicitly indicated in the structural formulae represented herein, are intended to be included within the scope of the present invention.
- stereochemically isomeric forms of compounds of the present invention defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of the present invention may possess.
- chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound.
- All stereochemically isomeric forms of the compounds of the present invention both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.
- stereoisomerically pure concerns compounds or intermediates having a stereoisomeric excess of at least 80% (i e minimum 90% of one isomer and maximum 10% of the other possible isomers) up to a stereoisomeric excess of 100% (i.e.
- Pure stereoisomeric forms of the compounds and intermediates of this invention may be obtained by the application of art-known procedures.
- enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof are tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphosulfonic acid.
- enantiomers may be separated by chromatographic techniques using chiral stationary phases.
- Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
- said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
- the diastereomeric racemates of formula (I) can be obtained separately by conventional methods.
- Appropriate physical separation methods that may advantageously be employed are, for example, selective crystallization and chromatography, e.g. column chromatography.
- the present invention is also intended to include all isotopes of atoms occurring on the present compounds.
- Isotopes include those atoms having the same atomic number but different mass numbers.
- isotopes of hydrogen include tritium and deuterium.
- isotopes of carbon include C-13 and C-14.
- the present compounds or similar term is meant to include the compounds of general formula (I), (I*), (Ia), (Ib), (Ic) and (Id), salts, stereoisomeric forms and racemic mixtures or any subgroups thereof.
- the present invention relates to compounds of Formula (I)
- the invention further provides compound of Formula (I)
- At least one R 4 represents Fluor, and one other R 4 is selected from the group consisting of C 1 -C 3 alkyl, C 1 -C 3 alkenyl, CHF 2 or cyclopropyl.
- one R 4 represents Fluor and one other R 4 is selected from the group consisting of methyl or CHF 2 , preferably methyl, and wherein the location of said Fluor is on the para position and the location of said methyl or CHF 2 is on the meta position related to the Nitrogen (*) as indicated In Formula (I*) below.
- the invention provides compound of Formula (I) wherein at least one R 4 represents Fluor, and one other R 4 is selected from the group consisting of C 1 -C 3 alkyl, C 1 -C 3 alkenyl, CHF 2 or cyclopropyl; more preferably, one R 4 represents Fluor and one other R 4 is selected from the group consisting of methyl or CHF 2 and wherein the location of said Fluor is on the para position and the location of said methyl or CHF 2 is on the meta position related to the Nitrogen (*) and R 2 represents a 4-7 membered saturated ring containing carbon and one or more oxygen atoms, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, C 1 -C 4 alkyloxycarbonyl, C( ⁇ O)—C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN
- R 2 represents a 4-7 membered saturated ring containing carbon and one or more oxygen atoms
- such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, C 1 -C 4 alkyloxy, C 1 -C 4 alkyloxycarbonyl, C( ⁇ O)—C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 .
- a preferred substituent for such a 4-7 membered saturated ring containing carbon and one or more oxygen atoms is C 1 -C 4 alkyl.
- the saturated ring is a 4, 5 or 6 membered ring.
- R 2 represents a 4-7 membered saturated ring containing carbon and one or more nitrogen atoms, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, C 1 -C 4 alkyloxy, C 1 -C 4 alkyloxycarbonyl, C( ⁇ O)—C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3
- R 2 represents a 4-7 membered saturated ring containing carbon and one or more oxygen atoms, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, C 1 -C 4 alkyloxy, C 1 -C 4 alkyloxycarbonyl, C( ⁇ O)—C 1 -C 3
- any optional substituent on such 3-7, 4-7 and 5-7 membered saturated ring, 6-10 membered bicyclic or bridged ring, C 1 -C 6 alkyl-R 5 or C 1 -C 6 alkyl is independently selected from the group consisting of hydrogen, Fluoro, OH, C 1 -C 3 alkyl and CF 3 , most preferably from the group consisting of hydrogen C 1 -C 3 alkyl, Fluoro and CF 3 .
- compounds according to Formula (I) are provided wherein B represents phenyl or thiophene, optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, C 1 -C 3 alkyl, CN, CFH 2 , CF 2 H and CF 3 .
- R 1 , R 2 , R 4 are defined as in any one of the embodiments as described and R 3 is selected from the group comprising hydrogen, halogen, C 1 -C 3 alkyl, CN, CFH 2 , CF 2 H, CF 3 .
- R 3 represents Fluor or hydrogen, more preferably hydrogen.
- R 1 , R 2 and R 4 are defined as in any one of the embodiments as described.
- R 1 , R 2 and R 4 are defined as in any one of the embodiments described and R 3 is selected from the group comprising hydrogen, halogen, C 1 -C 3 alkyl, CN, CFH 2 , CF 2 H, CF 3 .
- the compounds according to the invention are envisioned for use in the prevention or treatment of an HBV infection in a mammal.
- the present invention provides compounds which can be represented by Formula (I):
- the invention relates to compounds according to Formula (I)
- the present invention additionally relates to compound of Formula (I)
- R 2 represents a 3-7 membered saturated ring, containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, oxo, C( ⁇ O)—C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 .
- R 2 represents a 4-7 membered saturated ring containing carbon and one or more oxygen atoms, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, C( ⁇ O)— C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 .
- R 1 and R 2 together with the Nitrogen to which they are attached form a 5-7 membered saturated ring, optionally containing one or more additional heteroatoms each independently selected from the group consisting of O, S and N, such 5-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, oxo, C( ⁇ O)—C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 .
- B represents phenyl or thiophene, optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, C 1 -C 3 alkyl, CN, CFH 2 , CF 2 H and CF 3 .
- At least one R 4 represents Fluor, C 1 -C 3 alkyl, CHF 2 or cyclopropyl.
- At least one R 4 represents methyl, i-propyl or cyclopropyl.
- one R 4 represents methyl, i-propyl or cyclopropyl and the other R 4 represents Fluor, or hydrogen.
- the position of R 4 preferably is meta and/or para (position indicated from —N ⁇ ).
- One specific embodiment is a compound of Formula (I) wherein one R 4 on the para position represents Fluor and the other one R 4 on the meta position represents Fluor or methyl (position indicated from —N ⁇ ).
- R 1 , R 2 , R 4 are defined as above and R 3 is selected from the group comprising hydrogen, halo, C 1 -C 3 alkyl, CN, CFH 2 , CF 2 H, CF 3 .
- R 3 represents Fluor or hydrogen.
- the invention further relates to compounds according to Formula (I)
- R 1 , R 2 , B are defined as above and each R 4 is independently selected from hydrogen, halo, C 1 -C 4 alkyloxy, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H, CF 3 or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N.
- B represents phenyl or thiophene, optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, C 1 -C 3 alkyl, CN, CFH 2 , CF 2 H and CF 3 .
- At least one R 4 represents Fluor, C 1 -C 3 alkyl, CHF 2 or cyclopropyl.
- at least one R 4 represents methyl, i-propyl or cyclopropyl.
- one R 4 represents methyl, i-propyl or cyclopropyl and the other R 4 represents Fluor, or hydrogen.
- the position of R 4 preferably is meta and/or para.
- One specific embodiment is a compound of Formula (I) wherein one R 4 on the para position represents Fluor and the other one R 4 on the meta position represents Fluor or methyl.
- R 1 represents hydrogen or C 1 -C 3 alkyl
- Each R 4 is independently selected from hydrogen, halo, C 1 -C 4 alkyloxy, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H, CF 3 or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N;
- R 6 represents a 4-7 membered saturated ring consisting of carbon atoms and one or more heteroatoms each independently selected from the group consisting of O or S, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, oxo, C( ⁇ O)—C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 .
- Preferred compounds according to the invention are compounds or a stereoisomer or tautomeric form thereof with a formula or reference to a formula selected from the following tables 1 and 2:
- the present invention concerns a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a compound of Formula (I) as specified herein, and a pharmaceutically acceptable carrier.
- a prophylactically effective amount in this context is an amount sufficient to prevent HBV infection in subjects being at risk of being infected.
- a therapeutically effective amount in this context is an amount sufficient to stabilize HBV infection, to reduce HBV infection, or to eradicate HBV infection, in infected subjects.
- this invention relates to a process of preparing a pharmaceutical composition as specified herein, which comprises intimately mixing a pharmaceutically acceptable carrier with a therapeutically or prophylactically effective amount of a compound of Formula (I), as specified herein.
- compositions of the present invention may be formulated into various pharmaceutical forms for administration purposes.
- compositions there may be cited all compositions usually employed for systemically administering drugs.
- an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
- a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
- These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection.
- any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets.
- solid pharmaceutical carriers are employed.
- the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
- Injectable solutions may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
- Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations intended to be converted, shortly before use, to liquid form preparations.
- the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.
- the compounds of the present invention may also be administered via oral inhalation or insufflation in the form of a solution, a suspension or a dry powder using any art-known delivery system.
- Unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- unit dosage forms are tablets (including scored or coated tablets), capsules, pills, suppositories, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.
- the compounds of Formula (I) are active as inhibitors of the HBV replication cycle and can be used in the treatment and prophylaxis of HBV infection or diseases associated with HBV.
- the latter include progressive liver fibrosis, inflammation and necrosis leading to cirrhosis, end-stage liver disease, and hepatocellular carcinoma.
- the compounds of Formula (I) or any subgroup thereof are useful in the inhibition of the HBV replication cycle, in particular in the treatment of warm-blooded animals, in particular humans, infected with HBV, and for the prophylaxis of HBV infections.
- the present invention furthermore relates to a method of treating a warm-blooded animal, in particular human, infected by HBV, or being at risk of infection by HBV, said method comprising the administration of a therapeutically effective amount of a compound of Formula (I).
- the compounds of Formula (I), as specified herein, may therefore be used as a medicine, in particular as medicine to treat or prevent HBV infection.
- Said use as a medicine or method of treatment comprises the systemic administration to HBV infected subjects or to subjects susceptible to HBV infection of an amount effective to combat the conditions associated with HBV infection or an amount effective to prevent HBV infection.
- the present invention also relates to the use of the present compounds in the manufacture of a medicament for the treatment or the prevention of HBV infection.
- an antiviral effective daily amount would be from about 0.01 to about 50 mg/kg, or about 0.01 to about 30 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing about 1 to about 500 mg, or about 1 to about 300 mg, or about 1 to about 100 mg, or about 2 to about 50 mg of active ingredient per unit dosage form.
- the present invention also concerns combinations of a compound of Formula (I) or any subgroup thereof, as specified herein with other anti-HBV agents.
- the term “combination” may relate to a product or kit containing (a) a compound of Formula (I), as specified above, and (b) at least one other compound capable of treating HBV infection (herein designated as anti-HBV agent), as a combined preparation for simultaneous, separate or sequential use in treatment of HBV infections.
- anti-HBV agent a compound capable of treating HBV infection
- the invention concerns combination of a compound of Formula (I) or any subgroup thereof with at least one anti-HBV agent.
- the invention concerns combination of a compound of formula (I) or any subgroup thereof with at least two anti-HBV agents.
- the invention concerns combination of a compound of formula (I) or any subgroup thereof with at least three anti-HBV agents. In a particular embodiment, the invention concerns combination of a compound of formula (I) or any subgroup thereof with at least four anti-HBV agents.
- anti-HBV agents such as interferon- ⁇ (IFN- ⁇ ), pegylated interferon- ⁇ , 3TC, adefovir or a combination thereof, and, a compound of formula (I) or any subgroup thereof can be used as a medicine in a combination therapy.
- IFN- ⁇ interferon- ⁇
- pegylated interferon- ⁇ 3TC
- adefovir a compound of formula (I) or any subgroup thereof
- a compound of formula (I) or any subgroup thereof can be used as a medicine in a combination therapy.
- a carboxylic acid chloride of general Formula II can be selectively reacted with an aniline of general formula III, for example in an organic solvent like CH 2 Cl 2 in the presence of an organic base like triethylamine or DIPEA (N,N-diisopropylethylamine), or, as another example, by addition of the aniline III to a refluxing toluene solution of compound II, resulting in compound IV.
- the remaining sulfonic acid chloride functionality in compound IV is further reacted with an amine of general formula V, resulting in a compound of general Formula (I).
- a compound of general Formula (I) might be obtained as described in scheme 2.
- the sulfonic acid chloride VI is reacted with an amine of general formula V, for example in an organic solvent like CH 2 Cl 2 in the presence of an organic base like triethylamine or DIPEA or or, as another example, in the presence of Na 2 CO 3 in a mixture of H 2 O/THF.
- the formed compound VII is coupled with aniline of general formula III in the presence of an activating reagent like for example HATU and an organic base like triethylamine or DIPEA.
- compound IV can be reacted with an amino acid XI, in the presence of a base like NaOH, resulting in compound XII as described in scheme 4.
- This intermediate XII can then optionally be cyclised to compound XIII for example by heating with acetic anhydride and KOAc in toluene, or converting the carboxylic acid to an acid chloride followed by cyclisation in the presence of a base like triethylamine
- Suitable examples of amino acids of structure XI are derivatives of 5-aminopentanoic acid or 4-aminobutanoic acid
- a synthetic route to compounds of general formula XVI is described in Scheme 5.
- a aminoethanol derivative XIV, prepared as described in scheme 1 for the compounds of general Formula (I), is transformed in a aziridine derivative XV by treatment with Diethyl diazene-1,2-dicarboxylate and PPh 3 in THF.
- the aziridine of general formula XV is reacted with a nucleophile Nu, resulting in a compound of general formula XVI.
- nucleophiles (Nu) are, but are not limited to, morpholine and 1-methylpiperazine.
- Examples of a compound synthesized according to the route described in scheme 5, are compounds 116 and 117.
- An alternative method for the synthesis of compounds of general formula VII is via ester XVII as described in scheme 6.
- Reaction of XVII with amine V for example in an organic solvent like CH 2 Cl 2 or THF in the presence of an organic base like for example triethylamine or DIPEA, followed by hydrolysis of the ester, for example with LiOH in THF/H 2 O, followed by acidification, results in a compound of general formula VII.
- a compound of general formula VII, obtained via the route in scheme 2 or scheme 6, can be transformed to and acid chloride of formula XIX, for example by treatment with oxalyl chloride or thionyl chloride.
- a compound of general formula XIX can then be transformed to a compound of general Formula (I) by reaction with an aniline of general formula III.
- substitutents represented by R 4 in this general synthesis section are meant to include any substituent or reactive species that is suitable for transformation into any R 4 substitutent according to the present invention without undue burden for the person skilled in the art.
- Method A mobile phase A: H 2 O (0.1% TFA; B:CH 3 CN (0.05% TFA) Stop Time: 10 min; gradient time (min) [% A/% B]0.0 [100/0] to 1 [100/0] to 5 [40/60] to 7.5 [40/60] to 8.0 [100/0]; flow: 0.8 mL/min; column temp.: 50° C., YMC-PACK ODS-AQ, 50 ⁇ 2.0 mm 5 ⁇ m
- Method B mobile phase A: H 2 O (0.1% TFA; B:CH 3 CN (0.05% TFA) Stop Time: 10 min; gradient time (min) [% A/% B]0.0 [90/10] to 0.8 [90/10] to 4.5 [20/80] to 7.5 [20/80] to 8.0 [90/10]; flow: 0.8 mL/min; column temp.: 50° C., YMC-PACK ODS-AQ, 50 ⁇ 2.0 mm 5 ⁇ m
- Method D mobile phase A: H 2 O (0.05% NH 3 .H 2 O); B: CH 3 CN Stop Time: 10 min; gradient time (min) [% A/% B]0.0 [100/0] to 1 [100/0] to 5 [40/60] to 7.5 [40/60]; 8 [100/0] flow: 0.8 mL/min; column temp.: 40° C., XBridge Shield-RP18, 50*2.1 mm 5 ⁇ m
- Method F The LC measurement was performed using an Acquity UPLC (Waters) system with column heater (set at 55° C.). Reversed phase UPLC (Ultra Performance Liquid Chromatography) was carried out on a bridged ethylsiloxane/silica hybrid (BEH) C18 column (1.7 ⁇ m, 2.1 ⁇ 50 mm; Waters Acquity) with a flow rate of 0.8 mL/min. Two mobile phases (10 mM ammonium acetate in H 2 O/acetonitrile 95/5; mobile phase B: acetonitrile) were used to run a gradient condition from 95% A and 5% B to 5% A and 95% B in 1.3 minutes and hold for 0.3 minutes. An injection volume of 0.5 ⁇ l was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
- Method G The LC measurement was performed using an Acquity UPLC (Waters) with column heater (set at 55° C.). Reversed phase UPLC (Ultra Performance Liquid Chromatography) was carried out on a Acquity UPLC HSS T3 column (1.8 ⁇ m, 2.1 ⁇ 100 mm; Waters Acquity) with a flow rate of 0.8 mL/min.
- Acquity UPLC Waters
- Reversed phase UPLC Ultra Performance Liquid Chromatography
- Two mobile phases (A: 10 mM ammonium acetate in H 2 O/acetonitrile 95/5; mobile phase B: acetonitrile) were used to run a gradient condition from 100% A and 0% B to 5% A and 95% B in 2.1 minutes and subsequently to 0% A and 100% B in 0.9 minutes to 5% A and 95% B in 0.5 min.
- An injection volume of 1 ⁇ l was used.
- Cone voltage was 30 V for positive ionization mode and 30 V for negative ionization mode.
- Method H Reversed phase HPLC was carried out on an Atlantis C18 column (3.5 ⁇ m, 4.6 ⁇ 100 mm) with a flow rate of 1.6 mL/min. Column heater was set at 45° C. Two mobile phases (mobile phase A: 70% methanol+30% H 2 O; mobile phase B: 0.1% formic acid in H 2 O/methanol 95/5) were employed to run a gradient condition from 100% B to 5% B+95% A in 9 minutes and hold these conditions for 3 minutes. An injection volume of 10 ⁇ l was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
- 3-ethyloxetan-3-amine 3-ethyloxetane-3-carboxylic acid (3.0 g, 23.1 mmol), DPPA (Diphenylphosphoryl azide, 7.61 g, 27.7 mmol), triethylamine (3.0 g, 23.1 mmol) and BnOH (2.99 g, 27.7 mmol) were dissolved in toluene (50 mL). The mixture was stirred at 110° C. overnight. The solvent was removed in vacuo. Dichloromethane (50 mL) was added. The mixture was washed with 1N HCl (20 mL). The aqueous layer was extracted with dichloromethane (20 mL).
- N-(4-fluorophenyl)-3-sulfamoylbenzamide 1.6 g.
- Dichloromethane (20 mL) was added and the solid was filtered off.
- N-Chlorosuccinimide (3.42 g, 25.6 mmol) was added to the mixture of 6-(benzylthio)-N-phenylpicolinamide (2 g, 6.24 mmol) in acetic acid (60 mL) and water (40 mL). The reaction mixture was stirred at room temperature for 3 hours. The reaction was diluted with CH 2 Cl 2 (100 mL). After washing with water, the organic layer was added to the mixture of cyclohexanamine (12.4 g, 125 mmol) and Et 3 N (50 mL) in CH 2 Cl 2 (200 mL). The resulting mixture was stirred at room temperature for 4 hours.
- N-Chlorosuccinimide (2.56 g, 19.2 mmol) was added to a mixture of 2-(benzylthio)-N-phenylisonicotinamide (1.5 g, 4.68 mmol) in acetic acid (20 mL) and water (10 mL). The reaction mixture was stirred at room temperature for 4 hours. The reaction was diluted with CH 2 Cl 2 (20 mL). After washing with water, the organic layer was added to the mixture of cyclohexanamine (4.641 g, 46.8 mmol) and Et 3 N (10 mL, 71.74 mmol) in CH 2 Cl 2 (50 mL). The resulting mixture was stirred at room temperature for 4 hours.
- HATU (0.76 g, 2.0 mmol) was then added to a mixture of 4-(N-cyclohexylsulfamoyl)-picolinic acid (380 mg, 1.34 mmol), aniline (251 mg, 2.7 mmol) and DIPEA (0.517 g, 4.0 mmol) in DMF (50 mL) at room temperature The resulting mixture was stirred at room temperature for 18 hour. The mixture was diluted with water (200 mL), and extracted with EtOAc. The organic layers were washed with brine, dried over MgSO 4 , filtered and concentrated in vacuo.
- N-(3-bromo-4-fluorophenyl)-3-(N-isopropylsulfamoyl)benzamide (1.5 g, 3.61 mmol), ethynyltrimethylsilane (1.77 g, 18.06 mmol), Pd(PPh 3 ) 2 Cl 2 (0.127 g, 0.181 mmol) and copper iodide (34.4 mg, 0.181 mmol) were dissolved in diisopropylamine (10 mL). The mixture was stirred at 80° C. in autoclave for 24 hours. The solvent was removed in vacuo and dichloromethane (30 mL) was added.
- N-(4-fluoro-3-((trimethylsilyl)ethynyl)phenyl)-3-(N-isopropylsulfamoyl)benzamide (0.8 g, 1.66 mmol) and TFA (4 mL) were dissolved in anhydrous CH 2 Cl 2 (16 mL). The mixture was stirred at 25° overnight. The mixture was concentrated resulting in crude N-(3-ethynyl-4-fluorophenyl)-3-(N-isopropylsulfamoyl)benzamide which was used as such in the next step (650 mg).
- the reaction mixture was diluted with ethyl acetate (20 mL) and the catalyst was filtered off. The filtrate was concentrated in vacuo. Water (20 mL) was added and the aqueous layer was extracted with ethyl acetate (2 ⁇ 20 mL). The combined organic layers were washed with brine and dried over Na 2 SO 4 . The solvent was removed in vacuo and the obtained residue was purified by preparative high performance liquid chromatography over reversed phase C-18 (eluent: CH 3 CN in H 2 O (0.1% TFA) from 40% to 70%, v/v). The pure fractions were collected and the organic solvent was removed in vacuo.
- N-(4-fluoro-3-(prop-1-en-2-yl)phenyl)-3-(N-iso-propylsulfamoyl)benzamide 300 mg.
- N-(4-fluoro-3-(prop-1-en-2-yl)phenyl)-3-(N-isopropylsulfamoyl)benzamide 180 mg
- Pd/C (wet) 20 mg
- 3-methyloxetan-3-amine hydrochloride (210 mg, 1.7 mmol) and NaOH (204 mg, 5.1 mmol) were dissolved in 2-methyltetrahydrofuran (5 mL) and H 2 O (5 mL).
- 5-chlorosulfonyl-2-methyl-benzoic acid 400 mg, 1.7 mmol was added at 0° C.
- the mixture was stirred at 20° C. for 4 hours.
- the mixture was extracted with ethyl acetate (3 ⁇ 100 mL).
- 3-(isopropylsulfamoyl)benzoic acid (190 mg, 0.78 mmol) was dissolved in dichloromethane (5 mL). 3-fluoro-4-methoxyaniline (139 mg, 0.94 mmol) and triethylamine (112 mg, 1 mmol) were added to the mixture at 20° C. The mixture was stirred at 20° C. for 5 minutes. HATU (358 mg, 0.94 mmol) was added to the mixture at 20° C. The mixture was stirred at 20° C. for 8 hours. The solvent was removed in vacuo and the obtained residue was purified by high performance liquid chromatography (Column: Phenomenex Synergi C18 150*20 mm*Sum..
- Compound 224 was prepared similarly as described for compound 223, using 1-(4-pyridyl)propan-2-amine instead of 1-(2-pyridyl)propan-2-amine Compound 224 was purified by preparative high-performance liquid chromatography (column: Luna 150*30 mm*4 u, mobile phase: CH 3 CN in water (0.05% NH 4 HCO 3 ) from 40% to 70%). Method A; Rt: 4.6 min. m/z: 428.3 (M+H) + Exact mass: 427.1.
- 3-chlorosulfonyl-2-methyl-benzoic acid (commercial from Enamine EN300-109516; 508.4 mg, 2.17 mmol) was dissolved in dichloromethane (50 mL). DMF (1 drop) and oxalylchloride (1375 mg, 10.83 mmol) were added and the mixture was stirred for 4 hours under an inert atmosphere. The reaction mixture was concentrated resulting in 3-chlorosulfonyl-2-methyl-benzoyl chloride as a yellow oil (554 mg) which was used as such in the next step.
- Procedure S1 A solution of 3-[(4-fluoro-3-methyl-phenyl)carbamoyl]benzenesulfonyl chloride (0.50 g, 1.52 mmol, 1 eq) in toluene (10 mL) was added to a flask containing an amine (1.1 eq). DIPEA (657 ⁇ L, 3.81 mmol, 2.5 eq) was added and the reaction mixture was stirred for 1 hour. Next, 1M HCl (5 mL) was added to the reaction mixture.
- Procedure S2 A tube was charged with 3-[(4-fluoro-3-methyl-phenyl)carbamoyl]-benzenesulfonyl chloride (250 mg, 0.76 mmol) and an amine (1.1 eq) and CH 2 Cl 2 (5 mL) was added. The solution was stirred, DIPEA (329 ⁇ L, 1.9 mmol, 2.5 eq) was added and the mixture was further stirred for 30 minutes. Then, HCl (1M aq/5 mL) was added and the mixture was stirred for 5 minutes more.
- Cis Enantiomers 134a and 134b N-(4-fluoro-3-methyl-phenyl)-3-[[(1R,3S)-3-hydroxycyclohexyl]sulfamoyl]benzamide or N-(4-fluoro-3-methyl-phenyl)-3-[[(1S,3R)-3-hydroxycyclohexyl]sulfamoyl]benzamide.
- 141a, 141c N-(4-fluoro-3-methyl-phenyl)-3-[[(1S,2S)-1-hydroxyindan-2-yl]-sulfamoyl]benzamide or N-(4-fluoro-3-methyl-phenyl)-3-[[(1R,2R)-1-hydroxyindan-2-yl]sulfamoyl]benzamide.
- 141b, 141d N-(4-fluoro-3-methyl-phenyl)-3-[[(1R,2S)-1-hydroxyindan-2-yl]sulfamoyl]benzamide or N-(4-fluoro-3-methyl-phenyl)-3-[[(1S,2R)-1-hydroxyindan-2-yl]sulfamoyl]benzamide.
- the mixture of 145c and 145d was further purified by Preparative SFC (Stationary phase: Chiralpak Diacel AD 30 ⁇ 250 mm), Mobile phase: CO 2 , EtOH with 0.4% iPrNH 2 ), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again yielding 145c (29 mg) and 145d (27 mg).
- 145a and 145b N-(4-fluoro-3-methyl-phenyl)-3-[[(1R,3S)-3-hydroxycyclopentyl]sulfamoyl]benzamide or N-(4-fluoro-3-methyl-phenyl)-3-[[(1S,3R)-3-hydroxycyclopentyl]sulfamoyl]benzamide.
- Racemic compound 179 was separated in enantiomers 179a and 179b by Preparative SFC (Stationary phase: Chiralpak Diacel AD 30 ⁇ 250 mm), Mobile phase: CO 2 , iPrOH with 0.4% iPrNH 2 ) The collected fractions were concentrated in vacuo resulting in compound 179a and 179b.
- 179a +6.1° (589 nm, c 0.6225 w/v %, MeOH, 20° C.).
- 179b ⁇ 6.1° (589 nm, c 0.506 w/v %, MeOH, 20° C.).
- 3-(isopropylsulfamoyl)benzoic acid 250 mg, 1.03 mmol
- 4-fluoro-3,5-dimethyl-aniline 157 mg, 1.13 mmol
- DIPEA 398 mg, 3.08 mmol
- acetonitrile 10 mL
- HATU 430 mg, 1.13 mmol
- EtOAc 100 mL was added and the mixture was washed with 1M HCl, sat NaHCO 3 and brine.
- the reaction mixture was poured into H 2 O (850 mL), and EtOAc (300 mL) was added. The mixture was stirred vigorously for 5 minutes. Both upper liquid layers were decanted from a residue. The separated water layer was combined with the residue, and extracted with EtOAc. Both upper liquid layers were decanted from the residue. The separated water layer was combined with the residue, and extracted again with EtOAc. The organic layers were combined, washed with satured NaCl and dried with Na 2 SO 4 , filtered off, evaporated, and co-evaporated with toluene.
- Triethylamine (0.206 mL, 0.00149 mol) was added to a stirring mixture of 2-fluoro-6-methyl-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid (0.15 g, 0.000495 mol) and CH 3 CN (10 mL) under N 2 -atm.
- HATU 0.207 g, 0.545 mmol
- 5-amino-2-fluorobenzonitrile (79.9 mg, 0.569 mmol) was added, and the reaction mixture was stirred at room temperature for 20 hours. The reaction was next continued at 50° C. for 4 hours.
- tert-butyl N-(3-chloro-4,5-difluoro-phenyl)carbamate 11.8 g.
- tert-butyl N-(3-chloro-4,5-difluoro-phenyl)carbamate 8.5 g, 0.0322 mol was added portion wise to stirring HCl (40 mL, 0.16 mol, 4 M in dioxane). The mixture was stirred at room temperature for 2 hours, then left standing for 65 hours. Stirring was continued for another 2 hours. The formed precipitate was filtered off, washed with dioxane (4 ⁇ ) and dried at 50° C.
- 3-chloro-4,5-difluoro-aniline hydrochloride (5.95 g).
- the separated organic layer was dried with MgSO 4 , filtered off, and evaporated.
- the obtained 3-chloro-4,5-difluoro-aniline (0.81 g) was used as such.
- Compound 192 was prepared similarly as described for compound 191, using 3-chloro-4,5-difluoro-aniline hydrochloride instead of 5-amino-2-fluorobenzonitrile.
- Oxalyl chloride (12.3 mL, 0.143 mol) was added dropwise to a stirring solution of 5-bromo-3-chlorosulfonyl-2-fluoro-6-methyl-benzoic acid (9.5 g) and DMF (0.111 mL) in CH 2 Cl 2 (100 mL). After addition, the reaction mixture was stirred at room temperature for 2 hours and 30 minutes. The volatiles were removed in vacuo, and co-evaporated with toluene. The obtained residue containing 5-bromo-3-chlorosulfonyl-2-fluoro-6-methyl-benzoyl chloride was used as such.
- reaction mixture was combined with a similar reaction mixture starting from 20 mg 5-bromo-N-(3-chloro-4,5-difluoro-phenyl)-2-fluoro-6-methyl-3-[[(1R)-2,2,2-trifluoro-1-methyl-ethyl]sulfamoyl]benzamide) allowed to reach room temperature and left standing for 15 minutes.
- the upper layer was isolated by means of a separation funnel, and evaporated.
- 3-(tert-butylsulfamoyl)-2-fluoro-6-methyl-benzoic acid was prepared similarly as described for 2-fluoro-6-methyl-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid, using tert-butylamine instead of 3-methyloxetan-3-amine.
- Compound 205 was prepared similar as described for compound 194, using 4-fluoro-3-methylaniline instead of 3,4-difluoroaniline and starting from 3-(tert-butylsulfamoyl)-2-fluoro-6-methyl-benzoic acid instead of 2-fluoro-6-methyl-3[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid.
- Compound 207 to 210 were prepared similarly as described for compound 196 using 6-chloro-2-fluoro-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid instead of 2,6-difluoro-3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]benzoic acid and the corresponding aniline instead of 3,4-difluoroaniline.
- 2-bromo-6-fluoro-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid and 6-bromo-2-fluoro-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid were prepared similarly as described for 2-chloro-6-fluoro-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid and 6-chloro-2-fluoro-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid, starting from 2-bromo-6-fluorobenzoic acid instead of 2-chloro-6-fluorobenzoic acid.
- Compound 212 was prepared similarly as described for compound 196 using 2-bromo-6-fluoro-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid instead of 2,6-difluoro-3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]benzoic acid and 4-fluoro-3-(trifluoromethyl)aniline instead of 3,4-difluoroaniline.
- 3-methyloxolan-3-amine hydrochloride (165.9 mg, 1.21 mmol) was added to a solution of 3-[(4-fluoro-3-methyl-phenyl)carbamoyl]benzenesulfonyl chloride (499 mg, 1.096 mmol) in dry CH 2 Cl 2 (20 mL) at room temperature.
- Et 3 N (381 ⁇ L) was then added dropwise to the reaction mixture and the reaction mixture was stirred at room temperature for 1 hour.
- the reaction mixture was diluted with EtOAc (250 mL).
- HCl 0.5 N 50 mL was added and the layers were separated. The organic layer was washed again with NaOH 0.5 N (30 mL).
- 3-methyl-3-oxetanamine hydrochloride (302.6 mg, 2.45 mmol) and Hunig's base (1.15 mL, 6.68 mmol) dissolved in CH 2 Cl 2 (2 mL) were added to a solution of methyl 5-(chlorosulfonyl)-2-furoate (thermo scientific, 500 mg, 2.23 mmol) in CH 2 Cl 2 (10 mL). The reaction mixture was stirred overnight at room temperature. The volatiles were removed under reduced pressure and the obtained residue was used as such.
- Compound 232 to 239 were prepared by slow addition of an aniline to a refluxing toluene solution of a 3-chlorosulfonylbenzoyl chloride derivative, followed by reaction with an amine in the presence of a base like NEt 3 or DIPEA, as described above.
- This slurry was cooled to ⁇ 10° C. (dry ice/acetone bath) and a solution of sodium nitrite (4.803 g, 69.62 mmol) in H 2 O (20 mL) was added very slowly (1 drop/5 sec) to the slurry, keeping the temperature below ⁇ 5° C.
- reaction mixture was diluted with CH 2 Cl 2 , washed with HCl 0.5 N, filtered on Extrelut NT3 and evaporated.
- the obtained residue was purified by column chromatography on silica gel (Grace Resolv 12 g, eluent: CH 2 Cl 2 :MeOH 100:0->95:5) resulting in compound 240 (136 mg) as a white solid, dried at 50° C. in vacuo.
- the anti-HBV activity was measured using a stable transfected cell line, HepG2.2.15. This cell line was described to secrete relatively consistent high levels of HBV virion particles, which have been shown to cause both acute and chronic infection and disease in chimpanzees.
- antiviral activity was determined by quantification of purified HBV DNA from secreted virions using realtime PCR and an HBV specific primer set and probe.
- the anti HBV activity was also measured using the HepG2.117 cell line, a stable, inducibly HBV producing cell line, which replicates HBV in the absence of doxicycline (Tet-off system).
- HBV replication was induced, followed by a treatment with serially diluted compound in 96-well plates in duplicate. After 3 days of treatment, the antiviral activity was determined by quantification of intracellular HBV DNA using realtime PCR and an HBV specific primer set and probe.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Furan Compounds (AREA)
- Epoxy Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12182076 | 2012-08-28 | ||
EP12182076.5 | 2012-08-28 | ||
EP12185055.6 | 2012-09-19 | ||
EP12185055 | 2012-09-19 | ||
EP12190837 | 2012-10-31 | ||
EP12190837.0 | 2012-10-31 | ||
EP13157230 | 2013-02-28 | ||
EP13157230.7 | 2013-02-28 | ||
EP13169574.4 | 2013-05-28 | ||
EP13169574 | 2013-05-28 | ||
PCT/EP2013/067829 WO2014033176A1 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/067829 A-371-Of-International WO2014033176A1 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/681,309 Continuation US10995064B2 (en) | 2012-08-28 | 2017-08-18 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150274653A1 true US20150274653A1 (en) | 2015-10-01 |
Family
ID=49085019
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/423,981 Abandoned US20150274653A1 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US14/423,963 Active US10676429B2 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US15/681,309 Active US10995064B2 (en) | 2012-08-28 | 2017-08-18 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US16/858,519 Abandoned US20200255373A1 (en) | 2012-08-28 | 2020-04-24 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US17/065,463 Abandoned US20210024462A1 (en) | 2012-08-28 | 2020-10-07 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/423,963 Active US10676429B2 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US15/681,309 Active US10995064B2 (en) | 2012-08-28 | 2017-08-18 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US16/858,519 Abandoned US20200255373A1 (en) | 2012-08-28 | 2020-04-24 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US17/065,463 Abandoned US20210024462A1 (en) | 2012-08-28 | 2020-10-07 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
Country Status (27)
Country | Link |
---|---|
US (5) | US20150274653A1 (de) |
EP (2) | EP2890375B1 (de) |
JP (5) | JP6505013B2 (de) |
KR (4) | KR20210081451A (de) |
CN (4) | CN113321632A (de) |
AP (2) | AP2015008249A0 (de) |
AR (2) | AR092270A1 (de) |
AU (5) | AU2013307337B2 (de) |
BR (2) | BR112015004205B1 (de) |
CA (2) | CA2880699A1 (de) |
CL (2) | CL2015000488A1 (de) |
CR (2) | CR20210079A (de) |
EA (2) | EA038942B1 (de) |
EC (2) | ECSP15007322A (de) |
GT (2) | GT201500020A (de) |
HK (2) | HK1208465A1 (de) |
IL (3) | IL236967A0 (de) |
JO (1) | JOP20130256B1 (de) |
MX (2) | MX2015002696A (de) |
NI (2) | NI201500029A (de) |
NZ (4) | NZ704752A (de) |
PH (3) | PH12015500317A1 (de) |
SG (4) | SG10201709133QA (de) |
TW (4) | TWI636036B (de) |
UA (2) | UA123256C2 (de) |
UY (2) | UY34993A (de) |
WO (2) | WO2014033170A1 (de) |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150266890A1 (en) * | 2012-08-28 | 2015-09-24 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US20160115149A1 (en) * | 2013-05-17 | 2016-04-28 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
WO2017155844A1 (en) | 2016-03-07 | 2017-09-14 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
US9873671B2 (en) | 2014-01-16 | 2018-01-23 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9884818B2 (en) | 2013-05-17 | 2018-02-06 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US9938236B2 (en) | 2012-12-27 | 2018-04-10 | Drexel University | Antiviral agents against HBV infection |
US10071961B2 (en) | 2013-10-23 | 2018-09-11 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10077239B2 (en) | 2015-09-29 | 2018-09-18 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10189846B2 (en) | 2016-06-10 | 2019-01-29 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10196376B2 (en) | 2011-12-21 | 2019-02-05 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US10213420B2 (en) | 2014-02-05 | 2019-02-26 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10428070B2 (en) | 2017-12-06 | 2019-10-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10441589B2 (en) | 2016-04-15 | 2019-10-15 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10537580B2 (en) | 2015-03-19 | 2020-01-21 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
US10723733B2 (en) | 2017-12-06 | 2020-07-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10729688B2 (en) | 2018-03-29 | 2020-08-04 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10865211B2 (en) | 2018-09-21 | 2020-12-15 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
WO2020255012A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10952978B2 (en) | 2017-08-28 | 2021-03-23 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
CA2942533C (en) | 2014-03-13 | 2020-12-08 | Indiana University Research And Technology Corporation | Hepatitis b core protein allosteric modulators |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
CN107001283B (zh) * | 2014-07-31 | 2021-05-25 | 国家健康与医学研究院 | Flt3受体拮抗剂 |
US9765050B2 (en) | 2014-12-30 | 2017-09-19 | Novira Therapeutics, Inc. | Pyridyl reverse sulfonamides for HBV treatment |
MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
PT3321265T (pt) | 2015-03-04 | 2020-07-07 | Gilead Sciences Inc | Compostos 4,6-diamino-pirido[3,2-d]pirimidina compounds e a sua utilização como moduladores de receptores do tipo toll |
MA42684A (fr) | 2015-08-26 | 2018-07-04 | Gilead Sciences Inc | Modulateurs deutérés du récepteur toll |
TWI786639B (zh) | 2015-09-15 | 2022-12-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
EP3458455B1 (de) | 2016-05-20 | 2021-06-16 | F. Hoffmann-La Roche AG | Neuartige pyrazinverbindungen mit sauerstoff-, schwefel- und stickstofflinker zur behandlung von infektionskrankheiten |
BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
US11738013B2 (en) | 2016-05-27 | 2023-08-29 | Gilead Sciences, Inc. | Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors |
EP3484885B1 (de) | 2016-07-14 | 2020-03-04 | H. Hoffnabb-La Roche Ag | Carboxy-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazin-verbindungen zur behandlung von infektionskrankheiten |
JP7051804B2 (ja) | 2016-07-14 | 2022-04-11 | エフ.ホフマン-ラ ロシュ アーゲー | 感染症の治療のための6,7-ジヒドロ-4H-ピラゾロ[1,5-a]ピラジン化合物と6,7-ジヒドロ-4H-トリアゾロ[1,5-a]ピラジン化合物 |
CN109476659B (zh) | 2016-07-14 | 2021-07-09 | 豪夫迈·罗氏有限公司 | 用于治疗感染性疾病的新的四氢吡唑并吡啶化合物 |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
JP6746776B2 (ja) | 2016-09-02 | 2020-08-26 | ギリアード サイエンシーズ, インコーポレイテッド | Toll様受容体調節剤化合物 |
CN109937201A (zh) | 2016-09-15 | 2019-06-25 | 组装生物科学股份有限公司 | 乙型肝炎核心蛋白调节剂 |
BR112019007450A2 (pt) | 2016-10-14 | 2020-07-07 | Precision Biosciences, Inc. | meganucleases modificadas específicas para sequências de reconhecimento no genoma do vírus da hepatite b |
US10821103B2 (en) | 2016-11-07 | 2020-11-03 | Arbutus Biopharma Corporation | Substituted pyridinone-containing trycyclic compounds, and methods using same |
CN109843855B (zh) * | 2016-11-08 | 2021-06-25 | 正大天晴药业集团股份有限公司 | 作为cccDNA抑制剂的磺酰胺类化合物 |
CN108264520B (zh) * | 2017-01-03 | 2021-12-07 | 上海长森药业有限公司 | 用于治疗乙型肝炎的化合物及其用途 |
TWI714820B (zh) | 2017-01-31 | 2021-01-01 | 美商基利科學股份有限公司 | 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型 |
JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
CA3048278A1 (en) * | 2017-02-07 | 2018-08-16 | Janssen Pharmaceutica Nv | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis |
RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
WO2018160878A1 (en) | 2017-03-02 | 2018-09-07 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
AU2018238138A1 (en) | 2017-03-21 | 2019-10-17 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
RU2666727C1 (ru) * | 2017-07-18 | 2018-09-12 | Андрей Александрович Иващенко | Ингибитор вируса гепатита В (ВГВ) |
CA3073376C (en) | 2017-08-22 | 2022-07-12 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
AR115131A1 (es) | 2017-11-02 | 2020-12-02 | Aicuris Gmbh & Co Kg | Altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb) |
CU20200037A7 (es) | 2017-11-02 | 2021-03-11 | Aicuris Gmbh & Co Kg | Derivados de indol-2-carboxamidas sustituidos con amino-tiazol activos contra el virus de la hepatitis b (vhb) |
CN109879799B (zh) * | 2017-12-06 | 2020-08-11 | 浙江司太立制药股份有限公司 | 含有4-羰氧基哌啶基的氨磺酰基苯甲酰胺类化合物及其制备方法 |
WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
CN109988126B (zh) * | 2017-12-29 | 2023-05-16 | 南京富润凯德生物医药有限公司 | 一种3-氨基-氧杂环丁烷衍生物及其制备方法和应用 |
CN111601788B (zh) * | 2018-02-09 | 2022-06-14 | 正大天晴药业集团股份有限公司 | 衣壳蛋白装配抑制剂、其药物组合物和用途 |
TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
CA3093888A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
WO2019206072A1 (zh) * | 2018-04-24 | 2019-10-31 | 浙江海正药业股份有限公司 | 磺酰胺芳基甲酰胺衍生物及其制备方法和用途 |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
EP3817818A1 (de) | 2018-07-06 | 2021-05-12 | Gilead Sciences, Inc. | Therapeutische heterocyclische verbindungen |
CN112384505A (zh) | 2018-07-06 | 2021-02-19 | 吉利德科学公司 | 治疗性的杂环化合物 |
EP4234030A3 (de) | 2018-07-13 | 2023-10-18 | Gilead Sciences, Inc. | Pd-1/pd-l1-inhibitoren |
EP3597637A1 (de) * | 2018-07-19 | 2020-01-22 | Irbm S.P.A. | Inhibitoren des hepatitis-b-virus |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
EP3860991A4 (de) * | 2018-10-05 | 2022-11-16 | Emory University | Monomere und multimere anti-hbv-mittel |
CN113195055A (zh) | 2018-10-22 | 2021-07-30 | 组装生物科学股份有限公司 | 用于hbv治疗的5元杂芳基甲酰胺化合物 |
CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
WO2020087107A1 (en) | 2018-10-31 | 2020-05-07 | The University Of Sydney | Compositions and methods for treating viral infections |
CA3116347A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
LT3873903T (lt) | 2018-10-31 | 2024-05-10 | Gilead Sciences, Inc. | Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai |
AR116947A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
AR116948A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
WO2020089460A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv) |
UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
UY38437A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv) |
AR116946A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) |
TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチドおよびそのプロドラッグ |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
EP3962914A1 (de) | 2019-04-30 | 2022-03-09 | AiCuris GmbH & Co. KG | Neuartige indol-2-carboxamide mit wirksamkeit gegen das hepatitis-b-virus (hbv) |
CA3138380A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel oxalyl piperazines active against the hepatitis b virus (hbv) |
AU2020265392A1 (en) | 2019-04-30 | 2021-12-23 | Aicuris Gmbh & Co. Kg | Novel indolizine-2-carboxamides active against the hepatitis B virus (HBV) |
BR112021021580A2 (pt) | 2019-04-30 | 2022-01-04 | Aicuris Gmbh & Co Kg | Fenil e piridil ureias inovadoras ativas contra o vírus da hepatite b (hbv) |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
SG11202112590WA (en) | 2019-05-24 | 2021-12-30 | Assembly Biosciences Inc | Pharmaceutical compositions for the treatment of hbv |
WO2020241814A1 (ja) * | 2019-05-29 | 2020-12-03 | 国立大学法人東京大学 | 抗ウイルス剤又はウイルスcccDNA形成阻害剤 |
US20220305115A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
WO2020255039A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives |
BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
WO2021046286A1 (en) * | 2019-09-04 | 2021-03-11 | Taigen Biotechnology Co., Ltd. | Hepatitis b antiviral agents |
CN117843811A (zh) | 2019-09-30 | 2024-04-09 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
WO2021130270A1 (en) | 2019-12-24 | 2021-07-01 | F. Hoffmann-La Roche Ag | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
BR112022015864A2 (pt) * | 2020-02-11 | 2023-01-17 | Ospedale San Raffaele Srl | Composto, composição farmacêutica, processo para a síntese de composto, uso de um composto e uso de uma composição |
TW202200161A (zh) | 2020-03-20 | 2022-01-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
CN113493441A (zh) * | 2020-04-03 | 2021-10-12 | 广东东阳光药业有限公司 | 新型螺环类化合物及其在药物中的应用 |
CN111393391B (zh) * | 2020-04-16 | 2022-07-26 | 南京安纳康生物科技有限公司 | 用于乙型肝炎病毒感染的抗病毒剂 |
CN111349056B (zh) * | 2020-04-16 | 2022-08-02 | 南京安纳康生物科技有限公司 | 用于乙型肝炎病毒感染的抗病毒剂 |
AR121905A1 (es) | 2020-04-22 | 2022-07-20 | Assembly Biosciences Inc | Compuestos de carboxamida heteroarilo de 5 miembros para el tratamiento del hbv |
WO2021216660A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
EP4139000A1 (de) | 2020-04-22 | 2023-03-01 | Assembly Biosciences, Inc. | Pyrazolcarboxamidverbindungen zur behandlung von hbv |
WO2021216661A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
CN116194144A (zh) | 2020-08-07 | 2023-05-30 | 吉利德科学公司 | 膦酰胺核苷酸类似物的前药及其药物用途 |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
JP2024518558A (ja) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ, インコーポレイテッド | TLR8調節化合物と抗HBV siRNA治療薬との組合せ |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023069545A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2023069544A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2023069547A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2023164181A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164183A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164179A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164186A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
CN115677545B (zh) * | 2022-10-28 | 2024-03-15 | 潍坊医学院 | 一种抗hbv磺胺苯甲酰胺类衍生物及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999009022A1 (en) * | 1997-08-18 | 1999-02-25 | Centaur Pharmaceuticals, Inc. | Furansulfonic acid derivatives and pharmaceutical compositions containing the same |
US20160051512A1 (en) * | 2013-04-03 | 2016-02-25 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US20160115149A1 (en) * | 2013-05-17 | 2016-04-28 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US20160115125A1 (en) * | 2013-05-17 | 2016-04-28 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
Family Cites Families (219)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1359583A (en) * | 1919-11-28 | 1920-11-23 | James W Doolittle | Force-feed oil-cup |
US1359596A (en) * | 1919-12-08 | 1920-11-23 | Pressure Proof Piston Ring Com | Piston-ring |
US3843662A (en) | 1971-12-09 | 1974-10-22 | Pfizer | 2-halo-5-(substituted piperidino sulfonyl)benzoic acids |
AU1508183A (en) | 1982-06-04 | 1983-12-08 | Beecham Group Plc | Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane |
EP0135545A1 (de) | 1983-02-19 | 1985-04-03 | Beecham Group Plc | Azabicycloalkyl-derivate von benzamid und anilid |
JPS62142164A (ja) | 1985-12-13 | 1987-06-25 | Ishihara Sangyo Kaisha Ltd | 4,5−ジクロロイミダゾ−ル系化合物及びそれらを含有する有害生物防除剤 |
IN164880B (de) * | 1986-01-30 | 1989-06-24 | Ishihara Sangyo Kaisha | |
US5272167A (en) | 1986-12-10 | 1993-12-21 | Schering Corporation | Pharmaceutically active compounds |
JP2606720B2 (ja) * | 1987-03-13 | 1997-05-07 | 石原産業株式会社 | イミダゾール系化合物及びそれらを含有する有害生物防除剤 |
CA1339133C (en) | 1987-03-13 | 1997-07-29 | Rikuo Nasu | Imidazole compounds and biocidal composition comprising the same for controlling harmful organisms |
US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
GB8904174D0 (en) | 1989-02-23 | 1989-04-05 | British Bio Technology | Compounds |
US4962101A (en) | 1989-08-21 | 1990-10-09 | Merck & Co., Inc. | 2-(Heterocyclylalkyl)phenyl carbapenem antibacterial agents |
GB9023082D0 (en) | 1990-10-24 | 1990-12-05 | Schering Agrochemicals Ltd | Fungicides |
GB9109557D0 (en) | 1991-05-02 | 1991-06-26 | Wellcome Found | Chemical compounds |
US5308826A (en) | 1993-04-22 | 1994-05-03 | Zeneca Limited | Herbicidal 4-substituted pyridyl-3-carbinols |
GB9405347D0 (en) * | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
JPH10504525A (ja) | 1994-05-27 | 1998-05-06 | ジェイムズ・ブラック・ファウンデーション・リミテッド | ガストリンとcck拮抗薬 |
US5795907A (en) | 1994-05-27 | 1998-08-18 | James Black Foundation Limited | Gastin and CCK receptor ligands |
KR0131723B1 (ko) * | 1994-06-08 | 1998-04-14 | 김주용 | 반도체소자 및 그 제조방법 |
US5763618A (en) | 1995-05-12 | 1998-06-09 | Konica Corporation | Manufacturing method of sulfides |
US5723411A (en) | 1995-10-31 | 1998-03-03 | E. I. Du Pont De Nemours And Company | Herbicidal pyridazinones |
DE19540995A1 (de) | 1995-11-03 | 1997-05-07 | Hoechst Ag | Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
GB9612884D0 (en) | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
WO1997049695A1 (en) | 1996-06-25 | 1997-12-31 | Smithkline Beecham P.L.C. | Sulfonamide derivatives as 5ht7 receptor antagonists |
AU5127098A (en) | 1996-11-29 | 1998-06-22 | Smithkline Beecham Plc | Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis |
US5939423A (en) | 1997-04-16 | 1999-08-17 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir |
US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
AU759255B2 (en) | 1998-01-29 | 2003-04-10 | Amgen, Inc. | PPAR-gamma modulators |
RU2202344C2 (ru) | 1998-03-26 | 2003-04-20 | Джапан Тобакко Инк. | Антагонисты ноцицептина, производные амида, аналгетик, способ инициирования антагонистического действия к ноцицептину, способ лечения боли, фармацевтические композиции |
US6251893B1 (en) | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
CN1152864C (zh) | 1999-01-15 | 2004-06-09 | 奥坦纳医药公司 | 具有pde-iv抑制活性的苯基菲啶类化合物 |
AU6068600A (en) | 1999-07-16 | 2001-02-05 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
DE60037664T2 (de) | 1999-08-10 | 2008-12-24 | The Chancellor, Masters And Scholars Of The University Of Oxford | Langkettige n-alkyl verbindungen und deren oxa-derivate zur verwendung als anitvirale mittel |
WO2001019788A2 (en) | 1999-09-17 | 2001-03-22 | Cor Therapeutics, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
AR025884A1 (es) | 1999-10-01 | 2002-12-18 | Takeda Pharmaceutical | Compuestos de amina ciclica, su produccion y su uso |
PL357109A1 (en) | 1999-12-28 | 2004-07-12 | Pfizer Products Inc. | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
WO2001055121A1 (fr) | 2000-01-28 | 2001-08-02 | Kaken Pharmaceutical Co., Ltd. | Dérivés d'azépine |
US6511980B2 (en) | 2000-05-05 | 2003-01-28 | Ortho Mcneil Pharmaceutical, Inc. | Substituted diamine derivatives useful as motilin antagonists |
EP1193268A1 (de) | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmazeutisch aktive Sulfonamidderivate mit sowohl lipophilen als auch ionisierbaren Gruppen als Inhibitoren von Protein-JunKinasen |
WO2002051410A2 (en) | 2000-12-22 | 2002-07-04 | Akzo Nobel N.V. | Phenylthiazole and thiazoline derivatives and their use as antiparasitics |
WO2002053566A1 (fr) | 2000-12-27 | 2002-07-11 | Sumitomo Pharmaceuticals Company, Limited | Composes de carbapenem |
AU2002248418A1 (en) * | 2001-02-09 | 2002-08-28 | Massachusetts Institute Of Technology | Methods of identifying agents that mediate polypeptide aggregation |
US6650463B2 (en) | 2001-03-13 | 2003-11-18 | Seiko Epson Corporation | Electrophoretic display device |
KR100713137B1 (ko) | 2001-06-28 | 2007-05-02 | 동화약품공업주식회사 | 신규의 2,4-디플루오로벤즈아미드 유도체 |
AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
DE10136043A1 (de) | 2001-07-25 | 2003-02-13 | Degussa | Verfahren zur Herstellung von modifiziertem Ruß |
US6956035B2 (en) | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
US7205407B2 (en) | 2001-11-20 | 2007-04-17 | Eli Lilly And Company | 3-Substituted oxindole β3 agonists |
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
CA2487891A1 (en) | 2002-06-05 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the activation of ap-1 and nfat |
RU2340605C2 (ru) | 2002-06-27 | 2008-12-10 | Ново Нордиск А/С | Арилкарбонильные производные в качестве терапевтических средств |
EP1531815B1 (de) | 2002-06-27 | 2014-09-24 | Novo Nordisk A/S | Glukokinase-aktivatoren |
WO2004011427A2 (en) | 2002-07-31 | 2004-02-05 | Smithkline Beecham Corporation | Substituted benzanilides as modulators of the ccr5 receptor |
AU2003256923A1 (en) | 2002-07-31 | 2004-02-16 | Smithkline Beecham Corporation | Substituted benzanilides as modulators of the ccr5 receptor |
US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
US7186735B2 (en) | 2002-08-07 | 2007-03-06 | Sanofi-Aventis Deutschland Gmbh | Acylated arylcycloalkylamines and their use as pharmaceuticals |
JP4399862B2 (ja) | 2002-08-09 | 2010-01-20 | 味の素株式会社 | 腸疾患および内臓痛の治療薬 |
US20040110802A1 (en) * | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
AU2003265886A1 (en) | 2002-09-06 | 2004-03-29 | Janssen Pharmaceutica N.V. | (1H-Benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine H4-receptor antagonists for the treatment of inflammatory and allergic disorders |
SE0202838D0 (sv) | 2002-09-24 | 2002-09-24 | Astrazeneca Ab | Chemical compounds |
WO2004058709A1 (en) | 2002-12-23 | 2004-07-15 | Millennium Pharmaceuticals, Inc. | Ccr8 inhibitors |
US7320989B2 (en) | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
JP4969238B2 (ja) | 2003-03-27 | 2012-07-04 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
EP1628970A2 (de) | 2003-04-30 | 2006-03-01 | The Institutes of Pharmaceutical Discovery, LLC | Heterocyklisch substituierte carbonsäuren als hemmer der protein-tyrosinphosphatase-1b |
US7592352B2 (en) | 2003-05-06 | 2009-09-22 | Smithkline Beecham Corporation | Substituted thieno and furo-pyridines |
TW200510405A (en) | 2003-05-13 | 2005-03-16 | Schering Corp | Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors |
EP1651595A2 (de) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitinligaseinhibitoren |
US20110275630A1 (en) | 2003-06-02 | 2011-11-10 | Abbott Laboratories | Isoindolinone kinase inhibitors |
JP2006527201A (ja) | 2003-06-06 | 2006-11-30 | スミスクライン・ビーチャム・コーポレイション | Il−8受容体アンタゴニスト |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
GB0319151D0 (en) | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
WO2005026129A1 (en) | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
US7498050B2 (en) | 2003-12-15 | 2009-03-03 | Kraft Foods Global Brands Llc | Edible spread composition and packaged product |
DE102004009238A1 (de) | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
US8404747B2 (en) | 2004-03-05 | 2013-03-26 | The General Hospital Corporation | Compositions and methods for modulating interaction between polypeptides |
WO2005105785A2 (en) | 2004-05-04 | 2005-11-10 | Novo Nordisk A/S | Indole derivatives for treatment of obesity |
US20090105218A1 (en) | 2004-05-29 | 2009-04-23 | 7Tm Pharma A/S | CRTH2 Receptor Ligands For Therapeutic Use |
US7750158B2 (en) | 2004-06-22 | 2010-07-06 | Schering Corporation | Cannabinoid receptor ligands |
JP4703649B2 (ja) | 2004-07-30 | 2011-06-15 | エグゼリクシス, インコーポレイテッド | 薬学的因子としてのピロール誘導体 |
DE102004042441A1 (de) | 2004-08-31 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Mit Aminosäuren substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
KR20070048798A (ko) | 2004-08-31 | 2007-05-09 | 아스트라제네카 아베 | 퀴나졸리논 유도체 및 이것의 b-raf 억제제로서의 용도 |
AR051387A1 (es) | 2004-10-13 | 2007-01-10 | Wyeth Corp | Analogos de anilino-pirimidina |
RU2007118523A (ru) | 2004-10-19 | 2008-11-27 | Новартис Вэксинс Энд Диагностикс Инк. (Us) | Производные индола и бензимидазола |
US7919487B2 (en) | 2004-11-10 | 2011-04-05 | Synta Pharmaceuticals Corporation | Heteroaryl compounds |
US20060122236A1 (en) | 2004-12-06 | 2006-06-08 | Wood Michael R | Substituted biaryl-carboxylate derivatives |
DE602005013819D1 (de) | 2004-12-22 | 2009-05-20 | Astrazeneca Ab | Pyridincarbonsäureamidderivate zur verwendung als antikrebsmittel |
TW200635899A (en) | 2004-12-22 | 2006-10-16 | Astrazeneca Ab | Chemical compounds |
FI117653B (fi) | 2005-02-21 | 2006-12-29 | Eigenor Oy | Menetelmä ja laitteisto liikkuvien kohteiden havaitsemiseksi tutkalla |
GB0510141D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
US7790726B2 (en) | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
JP2009508835A (ja) | 2005-09-16 | 2009-03-05 | アロー セラピューティクス リミテッド | ビフェニル誘導体及びc型肝炎の治療におけるその使用 |
US7629340B2 (en) | 2005-12-12 | 2009-12-08 | Smithkline Beecham Corporation | N-(6-membered aromatic ring)-amido anti-viral compounds |
CA2634940A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist |
US20090018118A1 (en) | 2005-12-29 | 2009-01-15 | Uros Urleb | Heterocyclic compounds |
WO2007131168A2 (en) | 2006-05-04 | 2007-11-15 | Institute For Hepatitis And Virus Research | Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus |
US20080021063A1 (en) | 2006-07-18 | 2008-01-24 | Kazantsev Aleksey G | Compositions and methods for modulating sirtuin activity |
US8153803B2 (en) * | 2006-07-18 | 2012-04-10 | The General Hospital Corporation | Compositions and methods for modulating sirtuin activity |
FR2903985B1 (fr) | 2006-07-24 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
FR2904316B1 (fr) | 2006-07-31 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. |
US20100016310A1 (en) * | 2006-08-17 | 2010-01-21 | Boehringer Ingelheim International Gmbh | Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors |
US20100113421A1 (en) | 2006-10-06 | 2010-05-06 | Williams Theresa M | Non-nucleoside reverse transcriptase inhibitors |
US8808702B2 (en) | 2006-12-13 | 2014-08-19 | Temple University-Of The Commonwealth System Of Higher Education | Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof |
US20100022517A1 (en) | 2006-12-18 | 2010-01-28 | Richards Lori A | Ophthalmic formulation of rho kinase inhibitor compound |
US8071779B2 (en) | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
FR2910473B1 (fr) | 2006-12-26 | 2009-02-13 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique. |
JP2008179621A (ja) | 2006-12-28 | 2008-08-07 | Taisho Pharmaceutical Co Ltd | 含窒素飽和複素環化合物 |
US9001047B2 (en) | 2007-01-07 | 2015-04-07 | Apple Inc. | Modal change based on orientation of a portable multifunction device |
JP2008184403A (ja) | 2007-01-29 | 2008-08-14 | Japan Health Science Foundation | 新規c型肝炎ウイルス阻害剤 |
PE20090188A1 (es) | 2007-03-15 | 2009-03-20 | Novartis Ag | Compuestos heterociclicos como moduladores de la senda de hedgehog |
US8097728B2 (en) | 2007-04-30 | 2012-01-17 | Philadelphia Health & Education Corporation | Iminosugar compounds with antiflavirus activity |
BRPI0811516A2 (pt) | 2007-05-04 | 2014-11-18 | Irm Llc | Compostos e composições como inibidores de c-kit e pdgfr cinase |
CN101328169B (zh) | 2007-06-18 | 2011-05-25 | 张中能 | 一种乙氧碳酰基-取代噻唑二氢嘧啶 |
US8597949B2 (en) * | 2007-07-28 | 2013-12-03 | The University Of Chicago | Methods and compositions for modulating RAD51 and homologous recombination |
CN101765425A (zh) * | 2007-08-02 | 2010-06-30 | 弗·哈夫曼-拉罗切有限公司 | 苯甲酰胺衍生物用于治疗cns障碍的用途 |
CN101429166B (zh) | 2007-11-07 | 2013-08-21 | 上海特化医药科技有限公司 | 喹唑啉酮衍生物及其制备方法和用途 |
AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
FR2926555B1 (fr) | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
FR2926556B1 (fr) | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
FR2926554B1 (fr) | 2008-01-22 | 2010-03-12 | Sanofi Aventis | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
FR2926553B1 (fr) | 2008-01-23 | 2010-02-19 | Sanofi Aventis | Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique |
CU20080028A6 (es) * | 2008-02-29 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus |
WO2009146013A1 (en) | 2008-03-31 | 2009-12-03 | Georgetown University | Myosin light chain phosphatase inhibitors |
CA2722075C (en) * | 2008-04-24 | 2015-11-24 | Banyu Pharmaceutical Co., Ltd. | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient |
US8299096B2 (en) | 2008-06-26 | 2012-10-30 | Inspire Pharmaceuticals, Inc. | Method for treating pulmonary diseases using rho kinase inhibitor compounds |
US20090325960A1 (en) | 2008-06-26 | 2009-12-31 | Fulcher Emilee H | Method for treating inflammatory diseases using rho kinase inhibitor compounds |
US20100008968A1 (en) | 2008-06-26 | 2010-01-14 | Lampe John W | Method for treating cardiovascular diseases using rho kinase inhibitor compounds |
US8207195B2 (en) | 2008-06-26 | 2012-06-26 | Inspire Pharmaceuticals, Inc. | Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds |
US8410147B2 (en) | 2008-06-26 | 2013-04-02 | Inspire Pharmaceuticals, Inc. | Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds |
US20090325959A1 (en) | 2008-06-26 | 2009-12-31 | Vittitow Jason L | Method for treating ophthalmic diseases using rho kinase inhibitor compounds |
JP2012500189A (ja) | 2008-08-15 | 2012-01-05 | エフ.ホフマン−ラ ロシュ アーゲー | ビアリールアミノテトラリン |
US9040488B2 (en) | 2008-09-02 | 2015-05-26 | Baruch S. Blumberg Institute | Imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity |
US8143269B2 (en) * | 2008-10-03 | 2012-03-27 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
WO2010043592A1 (en) | 2008-10-15 | 2010-04-22 | Revotar Biopharmaceuticals Ag | Lipase inhibitors for use for the treatment of obesity |
EP2362775B1 (de) | 2008-11-20 | 2015-08-05 | GlaxoSmithKline LLC | Chemische verbindungen |
EP2400969A4 (de) | 2008-12-04 | 2012-05-16 | Inspire Pharmaceuticals Inc | Verfahren zur behandlung von lungenerkrankungen mit rho-kinasehemmerverbindungen |
CA2748174A1 (en) | 2008-12-30 | 2010-07-08 | Arqule, Inc. | Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds |
WO2010088000A2 (en) | 2009-02-02 | 2010-08-05 | Angion Biomedica Corp. | Antifibrotic compounds and uses thereof |
WO2010123139A1 (ja) * | 2009-04-24 | 2010-10-28 | 持田製薬株式会社 | スルファモイル基を有するアリールカルボキサミド誘導体 |
JP2012527414A (ja) | 2009-05-19 | 2012-11-08 | バイエル・クロップサイエンス・アーゲー | 殺虫性アリールピロリン |
MX348817B (es) | 2009-05-27 | 2017-06-30 | Ptc Therapeutics Inc | Metodos para tratar cancer y estados no neoplasicos. |
BRPI1009034A2 (pt) | 2009-06-30 | 2019-09-24 | Siga Tech Inc | composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada a mesma |
US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
WO2011035143A2 (en) | 2009-09-17 | 2011-03-24 | The Regents Of The University Of Michigan | Methods and compositions for inhibiting rho-mediated diseases and conditions |
US9051296B2 (en) | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
CN102093320B (zh) | 2009-12-09 | 2013-08-28 | 扬子江药业集团上海海尼药业有限公司 | 一种可溶性环氧化物水解酶抑制剂 |
EP2523936A1 (de) | 2010-01-15 | 2012-11-21 | Boehringer Ingelheim International GmbH | Cb2 rezeptor-modulierende verbindungen |
WO2011088561A1 (en) | 2010-01-20 | 2011-07-28 | University Of Manitoba | Anti-viral compounds and compositions |
US20130045203A1 (en) | 2010-03-02 | 2013-02-21 | Emory University | Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP |
JP2013522192A (ja) | 2010-03-11 | 2013-06-13 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎の処置のための化合物 |
CN102206172B (zh) * | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
WO2011123609A1 (en) | 2010-03-31 | 2011-10-06 | Glaxo Group Limited | Imidazolyl-imidazoles as kinase inhibitors |
PT2566327T (pt) | 2010-05-07 | 2017-05-26 | Glaxosmithkline Llc | Indoles |
EP2580190A4 (de) | 2010-06-11 | 2014-04-16 | Goeran Wadell | Neue antivirale verbindungen |
US20130142827A1 (en) | 2010-06-25 | 2013-06-06 | Philadelphia Health & Education Corporation D/B/A | Induction of immune response |
EP2595665A1 (de) | 2010-07-19 | 2013-05-29 | Inspire Pharmaceuticals, Inc. | Bifunktionelle rho-kinase-inhibitor-verbindungen, zusammensetzung damit und anwendung davon |
JP2013536178A (ja) | 2010-07-26 | 2013-09-19 | ニューロセラピューティクス ファーマ, インコーポレイテッド | アリールスルホンアミド誘導体、組成物、および使用方法 |
CN103249305A (zh) | 2010-07-27 | 2013-08-14 | 印斯拜尔药品股份有限公司 | 使用前药形式的激酶抑制剂化合物治疗眼科疾病的方法 |
WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
WO2012033956A1 (en) | 2010-09-08 | 2012-03-15 | Mithridion, Inc. | Cognition enhancing compounds and compositions, methods of making, and methods of treating |
WO2012047856A2 (en) | 2010-10-04 | 2012-04-12 | Institute For Hepatitis And Virus Research | Novel inhibitors of secretion of hepatitis b virus antigens |
GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
EP2646439B1 (de) | 2010-12-02 | 2016-05-25 | Bristol-Myers Squibb Company | Neue alkylamide als hiv-bindungsinhibitoren |
WO2012080050A1 (en) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Solid forms of a phenoxybenzenesulfonyl compound |
GB201103419D0 (de) | 2011-02-28 | 2011-04-13 | Univ Aberdeen | |
RS60191B1 (sr) | 2011-04-08 | 2020-06-30 | Janssen Sciences Ireland Unlimited Co | Derivati pirimidina za tretman virusnih infekcija |
US8889716B2 (en) | 2011-05-10 | 2014-11-18 | Chdi Foundation, Inc. | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof |
US9399619B2 (en) * | 2011-07-01 | 2016-07-26 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against HBV infection |
EP2794565B1 (de) | 2011-12-21 | 2017-07-26 | Novira Therapeutics Inc. | Hepatitis-b-viruzide |
CN104302626B (zh) | 2012-01-06 | 2016-09-07 | 爱尔兰詹森科学公司 | 4,4-二取代的-1,4-二氢嘧啶及其作为治疗乙型肝炎的药物的用途 |
US9657013B2 (en) * | 2012-02-29 | 2017-05-23 | Baruch S. Blumberg Institute | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use |
RU2014142598A (ru) | 2012-03-31 | 2016-05-27 | Ф. Хоффманн-Ля Рош Аг | Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в |
US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
SG11201407336PA (en) | 2012-05-25 | 2015-03-30 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
AU2013267209B2 (en) | 2012-06-01 | 2017-02-02 | Baruch S. Blumberg Institute | Modulation of hepatitis B virus cccDNA transcription |
JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
TW201408652A (zh) | 2012-07-11 | 2014-03-01 | Hoffmann La Roche | 作爲RORc調節劑之芳基磺內醯胺衍生物 |
NZ704752A (en) * | 2012-08-28 | 2018-06-29 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
DK2890683T3 (en) | 2012-08-28 | 2017-01-30 | Janssen Sciences Ireland Uc | MERGED BICYCLIC SULFAMOYL DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B |
CA2881322A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
WO2014106019A2 (en) | 2012-12-27 | 2014-07-03 | Philadelphia Health & Education Corporation, D/B/A Drexel | Novel antiviral agents against hbv infection |
US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
TWI622592B (zh) | 2013-02-28 | 2018-05-01 | 衛材R&D企管股份有限公司 | 四氫咪唑並[1,5-d][1,4]氧氮雜卓衍生物 |
WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
EP2970340B1 (de) | 2013-03-14 | 2020-02-12 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase-hemmer |
EP2997032B1 (de) | 2013-05-17 | 2018-07-25 | F.Hoffmann-La Roche Ag | 6-verbrückte heteroaryldihydropyrimidine zur behandlung und prophylaxe von hepatitis-b-virus-infektionen |
CA2913509A1 (en) | 2013-05-28 | 2014-12-04 | Bayer Cropscience Aktiengesellschaft | Heterocyclic compounds as pest control agents |
EP3004090B1 (de) | 2013-05-28 | 2017-10-25 | Astrazeneca AB | Chemische verbindungen |
WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
SG11201600522UA (en) | 2013-07-25 | 2016-02-26 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
AU2014337298B2 (en) | 2013-10-18 | 2018-12-06 | Indiana University Research And Technology Corporation | Hepatitis B viral assembly effectors |
WO2015055764A1 (en) | 2013-10-18 | 2015-04-23 | Syngenta Participations Ag | 3-methanimidamid-pyridine derivatives as fungicides |
US9567299B2 (en) | 2013-10-23 | 2017-02-14 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
ES2777248T3 (es) | 2013-11-14 | 2020-08-04 | Novira Therapeutics Inc | Derivados de azepano y métodos de tratar infecciones por hepatitis B |
JO3466B1 (ar) | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
ES2721001T3 (es) | 2014-01-31 | 2019-07-26 | Cognition Therapeutics Inc | Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa |
AU2015214096B2 (en) | 2014-02-05 | 2021-02-11 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
AP2016009257A0 (en) | 2014-02-06 | 2016-06-30 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
EA030115B9 (ru) | 2014-03-07 | 2018-09-28 | Ф. Хоффманн-Ля Рош Аг | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b |
CA2942533C (en) | 2014-03-13 | 2020-12-08 | Indiana University Research And Technology Corporation | Hepatitis b core protein allosteric modulators |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
US9771358B2 (en) | 2014-03-28 | 2017-09-26 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
JP6710642B2 (ja) | 2014-05-30 | 2020-06-17 | チル ファーマシューティカル カンパニー リミテッド | Hbv阻害剤としてのジヒドロピリミジン縮環誘導体 |
DK3227262T3 (da) | 2014-12-02 | 2020-08-10 | Novira Therapeutics Inc | Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling |
WO2016109684A2 (en) | 2014-12-30 | 2016-07-07 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis b infections |
MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
AU2016232801A1 (en) | 2015-03-19 | 2017-10-12 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
CA2982811A1 (en) | 2015-04-17 | 2016-10-20 | Indiana University Research And Technology Corporation | Hepatitis b viral assembly effectors |
WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
CA3000197A1 (en) | 2015-09-29 | 2017-04-06 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
CN109251212A (zh) | 2017-07-14 | 2019-01-22 | 上海长森药业有限公司 | 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途 |
-
2013
- 2013-08-28 NZ NZ704752A patent/NZ704752A/en not_active IP Right Cessation
- 2013-08-28 EA EA201590457A patent/EA038942B1/ru unknown
- 2013-08-28 KR KR1020217019832A patent/KR20210081451A/ko not_active Application Discontinuation
- 2013-08-28 BR BR112015004205-8A patent/BR112015004205B1/pt not_active IP Right Cessation
- 2013-08-28 JP JP2015529005A patent/JP6505013B2/ja not_active Expired - Fee Related
- 2013-08-28 UA UAA201502767A patent/UA123256C2/uk unknown
- 2013-08-28 CN CN202110497637.6A patent/CN113321632A/zh active Pending
- 2013-08-28 MX MX2015002696A patent/MX2015002696A/es active IP Right Grant
- 2013-08-28 SG SG10201709133QA patent/SG10201709133QA/en unknown
- 2013-08-28 EP EP13756113.0A patent/EP2890375B1/de active Active
- 2013-08-28 CN CN202110497671.3A patent/CN113444063A/zh active Pending
- 2013-08-28 MX MX2015002697A patent/MX2015002697A/es active IP Right Grant
- 2013-08-28 US US14/423,981 patent/US20150274653A1/en not_active Abandoned
- 2013-08-28 CN CN201380044856.2A patent/CN104812743A/zh active Pending
- 2013-08-28 AP AP2015008249A patent/AP2015008249A0/xx unknown
- 2013-08-28 EA EA201590450A patent/EA027280B1/ru unknown
- 2013-08-28 US US14/423,963 patent/US10676429B2/en active Active
- 2013-08-28 TW TW102130781A patent/TWI636036B/zh not_active IP Right Cessation
- 2013-08-28 NZ NZ74346313A patent/NZ743463A/en not_active IP Right Cessation
- 2013-08-28 NZ NZ74349913A patent/NZ743499A/en not_active IP Right Cessation
- 2013-08-28 CR CR20210079A patent/CR20210079A/es unknown
- 2013-08-28 UY UY0001034993A patent/UY34993A/es not_active Application Discontinuation
- 2013-08-28 AU AU2013307337A patent/AU2013307337B2/en not_active Ceased
- 2013-08-28 NZ NZ704748A patent/NZ704748A/en not_active IP Right Cessation
- 2013-08-28 KR KR1020157005867A patent/KR102122357B1/ko active IP Right Grant
- 2013-08-28 UY UY0001034992A patent/UY34992A/es not_active Application Discontinuation
- 2013-08-28 SG SG11201501362PA patent/SG11201501362PA/en unknown
- 2013-08-28 TW TW108104154A patent/TW201920090A/zh unknown
- 2013-08-28 TW TW102130779A patent/TWI696606B/zh not_active IP Right Cessation
- 2013-08-28 TW TW107129929A patent/TW201900607A/zh unknown
- 2013-08-28 UA UAA201502766A patent/UA122385C2/uk unknown
- 2013-08-28 JP JP2015529007A patent/JP2015533782A/ja not_active Withdrawn
- 2013-08-28 AR ARP130103057A patent/AR092270A1/es not_active Application Discontinuation
- 2013-08-28 BR BR112015004192-2A patent/BR112015004192B1/pt not_active IP Right Cessation
- 2013-08-28 EP EP13756110.6A patent/EP2890688A1/de not_active Withdrawn
- 2013-08-28 WO PCT/EP2013/067821 patent/WO2014033170A1/en active Application Filing
- 2013-08-28 CR CR20200276A patent/CR20200276A/es unknown
- 2013-08-28 JO JOP/2013/0256A patent/JOP20130256B1/ar active
- 2013-08-28 CA CA2880699A patent/CA2880699A1/en not_active Abandoned
- 2013-08-28 KR KR1020157005871A patent/KR102122244B1/ko active IP Right Grant
- 2013-08-28 AP AP2015008248A patent/AP2015008248A0/xx unknown
- 2013-08-28 AR ARP130103056A patent/AR092269A1/es not_active Application Discontinuation
- 2013-08-28 CN CN201380045665.8A patent/CN104902885A/zh active Pending
- 2013-08-28 AU AU2013307331A patent/AU2013307331A1/en not_active Abandoned
- 2013-08-28 SG SG11201501359TA patent/SG11201501359TA/en unknown
- 2013-08-28 WO PCT/EP2013/067829 patent/WO2014033176A1/en active Application Filing
- 2013-08-28 SG SG10201605291WA patent/SG10201605291WA/en unknown
- 2013-08-28 CA CA2881057A patent/CA2881057C/en not_active Expired - Fee Related
- 2013-08-28 KR KR1020207016380A patent/KR102271574B1/ko active IP Right Grant
-
2015
- 2015-01-28 IL IL236967A patent/IL236967A0/en unknown
- 2015-01-29 IL IL23698915A patent/IL236989B/en active IP Right Grant
- 2015-01-30 GT GT201500020A patent/GT201500020A/es unknown
- 2015-01-30 GT GT201500021A patent/GT201500021A/es unknown
- 2015-02-13 PH PH12015500317A patent/PH12015500317A1/en unknown
- 2015-02-23 PH PH12015500387A patent/PH12015500387B1/en unknown
- 2015-02-27 CL CL2015000488A patent/CL2015000488A1/es unknown
- 2015-02-27 EC ECIEPI20157322A patent/ECSP15007322A/es unknown
- 2015-02-27 EC ECIEPI20157335A patent/ECSP15007335A/es unknown
- 2015-02-27 NI NI201500029A patent/NI201500029A/es unknown
- 2015-02-27 NI NI201500030A patent/NI201500030A/es unknown
- 2015-02-27 CL CL2015000487A patent/CL2015000487A1/es unknown
- 2015-09-21 HK HK15109247.5A patent/HK1208465A1/xx unknown
- 2015-11-03 HK HK15110806.6A patent/HK1210030A1/xx unknown
-
2017
- 2017-06-28 IL IL253225A patent/IL253225B/en active IP Right Grant
- 2017-08-18 US US15/681,309 patent/US10995064B2/en active Active
-
2018
- 2018-06-25 AU AU2018204597A patent/AU2018204597B2/en not_active Ceased
- 2018-09-07 AU AU2018226485A patent/AU2018226485B2/en not_active Ceased
- 2018-11-05 JP JP2018207904A patent/JP6895938B2/ja active Active
- 2018-11-05 JP JP2018208063A patent/JP6907173B2/ja active Active
-
2019
- 2019-10-16 PH PH12019502355A patent/PH12019502355A1/en unknown
-
2020
- 2020-02-19 AU AU2020201203A patent/AU2020201203A1/en not_active Abandoned
- 2020-04-24 US US16/858,519 patent/US20200255373A1/en not_active Abandoned
- 2020-10-07 US US17/065,463 patent/US20210024462A1/en not_active Abandoned
-
2021
- 2021-06-07 JP JP2021095380A patent/JP2021176846A/ja not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999009022A1 (en) * | 1997-08-18 | 1999-02-25 | Centaur Pharmaceuticals, Inc. | Furansulfonic acid derivatives and pharmaceutical compositions containing the same |
US20160051512A1 (en) * | 2013-04-03 | 2016-02-25 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US20160115149A1 (en) * | 2013-05-17 | 2016-04-28 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US20160115125A1 (en) * | 2013-05-17 | 2016-04-28 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
Non-Patent Citations (1)
Title |
---|
Kim, N., H. Chun, S. Park, J. Yang, J. Kim, and S. Ahn "Discovery of novel HCV polymerase inhibitors using pharmacophore-based virtual screening" Bioorganic & Med. Chem. (2011), 21: pp. 3329-3334. * |
Cited By (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10196376B2 (en) | 2011-12-21 | 2019-02-05 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US10995064B2 (en) | 2012-08-28 | 2021-05-04 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US20150266890A1 (en) * | 2012-08-28 | 2015-09-24 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US10676429B2 (en) * | 2012-08-28 | 2020-06-09 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US9938236B2 (en) | 2012-12-27 | 2018-04-10 | Drexel University | Antiviral agents against HBV infection |
US10941113B2 (en) | 2013-02-28 | 2021-03-09 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10398677B2 (en) | 2013-04-03 | 2019-09-03 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US9884818B2 (en) | 2013-05-17 | 2018-02-06 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10160743B2 (en) * | 2013-05-17 | 2018-12-25 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10457638B2 (en) | 2013-05-17 | 2019-10-29 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US20160115149A1 (en) * | 2013-05-17 | 2016-04-28 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10071961B2 (en) | 2013-10-23 | 2018-09-11 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10377709B2 (en) | 2013-10-23 | 2019-08-13 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US9873671B2 (en) | 2014-01-16 | 2018-01-23 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10632112B2 (en) | 2014-02-05 | 2020-04-28 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
US10213420B2 (en) | 2014-02-05 | 2019-02-26 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10537580B2 (en) | 2015-03-19 | 2020-01-21 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10702528B2 (en) | 2015-07-13 | 2020-07-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10077239B2 (en) | 2015-09-29 | 2018-09-18 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10934306B2 (en) | 2016-03-07 | 2021-03-02 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
IL261599A (en) * | 2016-03-07 | 2018-10-31 | Enanta Pharm Inc | Substances active against the virus hepatitis b. |
WO2017155844A1 (en) | 2016-03-07 | 2017-09-14 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
US10538532B2 (en) | 2016-03-07 | 2020-01-21 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
AU2017229007B2 (en) * | 2016-03-07 | 2021-04-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10179792B2 (en) | 2016-03-07 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10441589B2 (en) | 2016-04-15 | 2019-10-15 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
US11129834B2 (en) | 2016-04-15 | 2021-09-28 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
US10640511B2 (en) | 2016-06-10 | 2020-05-05 | Enant Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10189846B2 (en) | 2016-06-10 | 2019-01-29 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US11596611B2 (en) | 2017-08-28 | 2023-03-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10952978B2 (en) | 2017-08-28 | 2021-03-23 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10428070B2 (en) | 2017-12-06 | 2019-10-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10723733B2 (en) | 2017-12-06 | 2020-07-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
US10729688B2 (en) | 2018-03-29 | 2020-08-04 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US11377450B2 (en) | 2018-09-21 | 2022-07-05 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
US10865211B2 (en) | 2018-09-21 | 2020-12-15 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
US11891393B2 (en) | 2018-11-21 | 2024-02-06 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
WO2020255012A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives |
US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10995064B2 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | |
US10941113B2 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | |
US10160743B2 (en) | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | |
OA17199A (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B. | |
OA17200A (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: JANSSEN INFECTIOUS DISEASES BVBA, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RABOISSON, PIERRE JEAN-MARIE BERNARD;REEL/FRAME:035796/0772 Effective date: 20120828 Owner name: JANSSEN R&D IRELAND, IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JANSSEN PHARMACEUTICA NV;REEL/FRAME:035796/0796 Effective date: 20120828 Owner name: JANSSEN R&D IRELAND, IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JANSSEN INFECTIOUS DISEASES BVBA;REEL/FRAME:035796/0781 Effective date: 20120828 Owner name: JANSSEN INFECTIOUS DISEASES BVBA, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VANDYCK, KOEN;REEL/FRAME:035796/0716 Effective date: 20120828 Owner name: JANSSEN INFECTIOUS DISEASES BVBA, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LAST, STEFAAN JULIEN;REEL/FRAME:035796/0741 Effective date: 20120828 Owner name: JANSSEN PHARMACEUTICA NV, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROMBOUTS, GEERT;REEL/FRAME:035796/0743 Effective date: 20120828 Owner name: JANSSEN INFECTIOUS DISEASES BVBA, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VERSCHUEREN, WIM GASTON;REEL/FRAME:035796/0745 Effective date: 20120828 |
|
AS | Assignment |
Owner name: JANSSEN SCIENCES IRELAND UC, IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JANSSEN R&D IRELAND;REEL/FRAME:043348/0401 Effective date: 20141229 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |